General Information of Disease (ID: DIS51BK2)

Disease Name Pediatric lymphoma
Synonyms lymphoma; pediatric lymphoma; childhood lymphoma
Definition A Hodgkin or non-Hodgkin lymphoma that occurs during childhood.
Disease Hierarchy
DISN6V4S: Lymphoma
DISS6SNG: Malignant neoplasm
DIS51BK2: Pediatric lymphoma
Disease Identifiers
MONDO ID
MONDO_0003659
UMLS CUI
C1332979
MedGen ID
232062

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 222 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
ANXA8 TTSW16P Limited Altered Expression [1]
APOBEC3G TTP96KH Limited Altered Expression [2]
ASRGL1 TT4WT91 Limited Biomarker [3]
BTG1 TTL7N2W Limited Biomarker [4]
BUB1 TT78309 Limited Genetic Variation [5]
CASP5 TTWR48J Limited Genetic Variation [6]
CD22 TTM6QSK Limited Biomarker [7]
CD3G TTV3XPL Limited Genetic Variation [8]
CDC25A TTLZS4Q Limited Altered Expression [9]
CDC25B TTR0SWN Limited Genetic Variation [9]
CETP TTFQAYR Limited Altered Expression [10]
CXCL13 TT0NIZ1 Limited Biomarker [11]
F9 TTFEZ5Q Limited Genetic Variation [12]
FCER2 TTCH6MU Limited Altered Expression [13]
FES TTLBY21 Limited Biomarker [14]
FKBP1A TTMW94E Limited Biomarker [15]
HBB TTM6HK1 Limited Biomarker [16]
HEXA TTJI5JW Limited Genetic Variation [17]
HMBS TTT0HW3 Limited Genetic Variation [8]
ITK TT3C80U Limited Biomarker [18]
KLRC1 TTC4IMS Limited Genetic Variation [19]
LCK TT860QF Limited Altered Expression [20]
LYN TT1RWNJ Limited Biomarker [21]
MAD1L1 TTNE9U7 Limited Genetic Variation [22]
MAP3K19 TTRHJA3 Limited Genetic Variation [23]
MPL TTIHYA4 Limited Altered Expression [24]
MYCBP TTVW4XU Limited Biomarker [25]
NEDD8 TTNDC4K Limited Biomarker [26]
PMEL TT8MK59 Limited Genetic Variation [27]
PRLR TTBPXMA Limited Biomarker [28]
PSMB6 TT8EPLT Limited Genetic Variation [29]
PTGDR2 TTQDMX5 Limited Biomarker [30]
RICTOR TT143WL Limited Biomarker [31]
ROR1 TTDEJAU Limited Biomarker [32]
RTN4R TTVRZUO Limited Biomarker [33]
SELE TT1PL7M Limited Biomarker [34]
SERPING1 TTVQ6R9 Limited Biomarker [35]
SLC16A3 TTG6VD5 Limited Altered Expression [36]
SNAP25 TTYQWA0 Limited Biomarker [37]
SPN TTOZAX0 Limited Biomarker [38]
STAB1 TTJFEOC Limited Altered Expression [39]
TLR7 TTRJ1K4 Limited Biomarker [40]
TNFRSF17 TTZ3P4W Limited Altered Expression [41]
TNFSF13 TTOI1RM Limited Biomarker [42]
TSG101 TTHU7JA Limited Biomarker [43]
DCK TTJOCE4 Disputed Biomarker [44]
SLC22A2 TT0XOJN Disputed Biomarker [45]
ACVRL1 TTGYPTC moderate Biomarker [46]
BCL11A TTR61MW moderate Biomarker [47]
BCL2A1 TTGT9C7 moderate Altered Expression [48]
CXCL9 TTWE5PB moderate Biomarker [49]
EIF4EBP1 TTKGEBL moderate Altered Expression [50]
HSP90B1 TTFPKXQ moderate Genetic Variation [51]
IL1R1 TTWOTEA moderate Biomarker [52]
INPP5D TTTP2Z1 moderate Biomarker [53]
MTA1 TTO4HUS moderate Biomarker [54]
ODC1 TTUMGNO moderate Genetic Variation [55]
RPSA TTLUW5B moderate Altered Expression [56]
SYVN1 TT8XKYM moderate Biomarker [57]
TNFRSF10A TT5WLRX moderate Genetic Variation [58]
TNFRSF14 TTWGTC1 moderate Biomarker [59]
UCP1 TTI12YJ moderate Biomarker [60]
XPA TTGT87E moderate Genetic Variation [61]
ZAP70 TTUMHT8 moderate Altered Expression [62]
AICDA TTKRTP6 Strong Genetic Variation [63]
ALOX12 TT12ABZ Strong Genetic Variation [64]
ALPI TTHYMUV Strong Biomarker [65]
ATRAID TTFLIKM Strong Biomarker [66]
BAK1 TTFM7V0 Strong Genetic Variation [67]
BCL6 TTC9YX5 Strong Biomarker [68]
BIRC3 TTAIWZN Strong Altered Expression [69]
BTLA TTER58P Strong Biomarker [59]
C1QBP TTWTD7F Strong Biomarker [70]
CAPN1 TT1WBIJ Strong Biomarker [71]
CASR TTBUYHA Strong Genetic Variation [72]
CBX7 TTBN3HC Strong Altered Expression [73]
CCND3 TT1JXNR Strong Biomarker [74]
CD19 TTW640A Strong Biomarker [75]
CD27 TTDO1MV Strong Biomarker [18]
CD28 TTQ13FT Strong Biomarker [76]
CD33 TTJVYO3 Strong Biomarker [77]
CD37 TTFCW29 Strong Altered Expression [78]
CD38 TTPURFN Strong Biomarker [79]
CD40 TT1ERKL Strong Biomarker [80]
CD40LG TTIJP3Q Strong Biomarker [81]
CD47 TT28S46 Strong Biomarker [82]
CD70 TTNCIE0 Strong Biomarker [18]
CD74 TTCMYP9 Strong Altered Expression [83]
CD79B TTBN5I7 Strong Genetic Variation [84]
CD80 TT89Z17 Strong Altered Expression [85]
CDK2 TT7HF4W Strong Altered Expression [86]
CDK4 TT0PG8F Strong Altered Expression [87]
CDK7 TTQYF7G Strong Biomarker [88]
CDKN2C TTBRUGA Strong Biomarker [66]
CEL TTTRNQW Strong Genetic Variation [89]
CHEK1 TTTU902 Strong Biomarker [90]
CLEC4C TT7YT06 Strong Biomarker [91]
CNTN2 TT2Z1WB Strong Biomarker [92]
CRTC2 TTFWETR Strong Biomarker [93]
CSF1R TT7MRDV Strong Altered Expression [94]
CSNK2A1 TTER6YH Strong Biomarker [95]
CSNK2A2 TT7GR5W Strong Biomarker [95]
CTPS1 TTN12BZ Strong Biomarker [18]
DGKZ TTSBBXL Strong Biomarker [96]
EPHA4 TTG84D3 Strong Altered Expression [97]
EPHA7 TTAHTVG Strong Biomarker [98]
F11R TT3C8EG Strong Altered Expression [99]
F8 TT1290U Strong Biomarker [100]
FLT4 TTDCBX5 Strong Biomarker [101]
FOXP1 TT0MUCI Strong Biomarker [102]
GBA TT1B5PU Strong Biomarker [103]
GLB1 TTNGJPH Strong Altered Expression [104]
GPR34 TTVXSTQ Strong Altered Expression [105]
GRB2 TTEYRJ9 Strong Altered Expression [106]
GSK3A TTQWAU1 Strong Altered Expression [107]
GUCY2D TTWNFC2 Strong Biomarker [68]
GZMB TTKEPHX Strong Altered Expression [108]
HDAC6 TT5ZKDI Strong Altered Expression [109]
HDAC7 TTMUEK1 Strong Altered Expression [110]
HDAC9 TT8M4E1 Strong Biomarker [111]
HMGB2 TTA78JQ Strong Biomarker [112]
HPSE TTR7GJO Strong Biomarker [113]
HSP90AA1 TT78R5H Strong Genetic Variation [114]
HSPB8 TTY0OJN Strong Altered Expression [115]
HTR1A TTSQIFT Strong Biomarker [116]
IL1RL1 TT4GZA4 Strong Genetic Variation [117]
IL21R TTZO9B0 Strong Altered Expression [118]
ITGA4 TTJMF9P Strong Biomarker [119]
ITGAM TTB69FJ Strong Biomarker [120]
ITGB2 TTIJWR7 Strong Biomarker [120]
JAK3 TTT7PJU Strong Genetic Variation [121]
KAT6A TT6O1J0 Strong Genetic Variation [122]
KIR2DS1 TTVWAGF Strong Genetic Variation [123]
KIR2DS2 TTV3CFI Strong Genetic Variation [123]
KIR3DL2 TTQH3N0 Strong Genetic Variation [123]
LAIR1 TTSI7A8 Strong Biomarker [124]
LGALS1 TTO3NYT Strong Biomarker [125]
LY6K TT5GKHN Strong Biomarker [126]
MALT1 TTCI81G Strong Altered Expression [127]
MAP3K20 TTTUZ3O Strong Biomarker [128]
MAP3K7 TTJQT60 Strong Biomarker [129]
MCL1 TTL53M6 Strong Altered Expression [130]
MLH1 TTISG27 Strong Biomarker [131]
MLYCD TT9Z4YD Strong Biomarker [132]
MME TT5TKPM Strong Biomarker [133]
MS4A1 TTUE541 Strong Biomarker [134]
MSH2 TTCAWRT Strong Genetic Variation [135]
MVD TTE5J6X Strong Biomarker [136]
MYD88 TTB6Q2O Strong Genetic Variation [137]
NCF1 TTZ4JC3 Strong Biomarker [138]
NCR1 TTQNRJM Strong Biomarker [139]
NDUFA13 TTRU1NG Strong Altered Expression [140]
NFKB2 TTKLNRV Strong Biomarker [141]
NME1 TTDY8JH Strong Biomarker [142]
NPR2 TTNB7IF Strong Biomarker [103]
NR0B2 TT25A9Q Strong Posttranslational Modification [143]
NR1I3 TTRANFM Strong Genetic Variation [72]
PAX5 TTA4REJ Strong Biomarker [144]
PBK TTMY6BZ Strong Altered Expression [145]
PIM2 TT69J2Z Strong Biomarker [146]
PINX1 TT4FJ3A Strong Genetic Variation [147]
PKD2L1 TTAHD89 Strong Biomarker [101]
PLK4 TTGPNZQ Strong Biomarker [148]
PNP TTMCF1Y Strong Biomarker [149]
PPID TTNAFOU Strong Biomarker [150]
PREP TTNGKET Strong Biomarker [151]
PRKAR1A TTNAHEX Strong Genetic Variation [72]
PRMT5 TTR1D7X Strong Altered Expression [152]
PSMB9 TTOUSTQ Strong Biomarker [153]
PTGDR TTNVEIR Strong Genetic Variation [154]
PTK7 TTXH2ZN Strong Biomarker [155]
PTPN1 TTELIN2 Strong Genetic Variation [156]
PTPN13 TT405FP Strong Posttranslational Modification [157]
PTPN2 TTY8PUS Strong Biomarker [158]
PTPRC TTUS45N Strong Biomarker [68]
RAB7A TTF6WAQ Strong Altered Expression [159]
RIPK4 TTB4S01 Strong Biomarker [160]
RNF34 TTEWDK1 Strong Biomarker [161]
RORB TTGB2LZ Strong Altered Expression [162]
SENP1 TTW9HY5 Strong Biomarker [163]
SGPP1 TTN0VRB Strong Altered Expression [164]
SMYD2 TT7YJFO Strong Altered Expression [165]
SPHK2 TTCN0M9 Strong Biomarker [166]
STK38 TT27XFN Strong Altered Expression [167]
STK4 TTCPLVN Strong Biomarker [168]
SYK TT2HUPM Strong Biomarker [169]
TBL1XR1 TTYXT16 Strong Biomarker [170]
TCL1A TTUKRDV Strong Biomarker [171]
TERF1 TT1Y6J2 Strong Biomarker [172]
TIAM1 TTNU6I5 Strong Biomarker [173]
TIRAP TTKU0LS Strong Genetic Variation [174]
TK1 TTP3QRF Strong Biomarker [175]
TLR1 TTW14D0 Strong Biomarker [176]
TMEM97 TT9NXW4 Strong Biomarker [177]
TNFAIP3 TT5W0IO Strong Biomarker [178]
TNFRSF13B TTL9OD4 Strong Genetic Variation [179]
TNFRSF13C TT7NJSE Strong Biomarker [180]
TNFRSF18 TTG6LA7 Strong Biomarker [181]
TNFRSF4 TTL31H0 Strong Altered Expression [182]
TNFRSF9 TTPW9LJ Strong Biomarker [183]
TNFSF13B TTWMIDN Strong Genetic Variation [184]
TNFSF14 TTKVENM Strong Biomarker [185]
TRPV2 TTBECWA Strong Biomarker [186]
TYRO3 TTIEMFN Strong Altered Expression [187]
UCHL1 TTX9IFP Strong Biomarker [103]
WAS TTE8T73 Strong Genetic Variation [188]
ARRB1 TTMVD4A Definitive Biomarker [189]
ARRB2 TT8SO2I Definitive Biomarker [189]
BMP6 TT07RIB Definitive Posttranslational Modification [190]
CA12 TTSYM0R Definitive Altered Expression [191]
COPS5 TTSTNJR Definitive Altered Expression [192]
CR2 TT0HUN7 Definitive Biomarker [193]
DPP9 TTNDUL7 Definitive Altered Expression [194]
FMNL1 TTW20PQ Definitive Biomarker [195]
GRIA3 TT82EZV Definitive Altered Expression [196]
GRM3 TT8A9EF Definitive Altered Expression [196]
IL3RA TTENHJ0 Definitive Biomarker [197]
OPRK1 TTQW87Y Definitive Biomarker [198]
PDCD2 TTYOVWN Definitive Biomarker [199]
TRB TT84HCW Definitive Genetic Variation [200]
TYK2 TTBYWP2 Definitive Biomarker [201]
VTCN1 TTCK85E Definitive Altered Expression [202]
------------------------------------------------------------------------------------
⏷ Show the Full List of 222 DTT(s)
This Disease Is Related to 4 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
ABCB5 DTKVEXO Strong Altered Expression [203]
SLC27A5 DT0TQS3 Strong Genetic Variation [89]
SLC35A2 DT0567K Strong Genetic Variation [204]
SLC35B2 DT81RKJ Strong Altered Expression [205]
------------------------------------------------------------------------------------
This Disease Is Related to 7 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
UCK2 DETN1O0 Limited Altered Expression [206]
CES2 DETHCPD Strong Biomarker [207]
NAT1 DE7OAB3 Strong Biomarker [208]
NAT2 DER7TA0 Strong Genetic Variation [208]
PGPEP1 DEVDR46 Strong Biomarker [209]
SULT1E1 DESTKG6 Strong Biomarker [210]
THOP1 DE95LJC Strong Genetic Variation [211]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DME(s)
This Disease Is Related to 323 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ADA2 OTGCV24S Limited Biomarker [212]
ADAM28 OT3GBVHL Limited Biomarker [213]
ALLC OTZE4XV7 Limited Biomarker [214]
AMELX OTIN26MM Limited Biomarker [215]
AMH OT5FH4BD Limited Biomarker [216]
APAF1 OTJWIVY0 Limited Biomarker [217]
ASCC2 OT3B204T Limited Genetic Variation [27]
BLM OTEJOAJX Limited Biomarker [218]
BMF OT90NSLI Limited Biomarker [219]
BTG2 OTZF6K1H Limited Biomarker [4]
CARTPT OTTE4V9S Limited Genetic Variation [220]
CCDC34 OTZ3AGSQ Limited Altered Expression [221]
CD1D OT3ROU4J Limited Biomarker [222]
CD79A OTOJC8DV Limited Biomarker [223]
CD99 OTPUZ5DE Limited Altered Expression [224]
CDKN2D OT2TTZPZ Limited Genetic Variation [12]
CHP1 OTHTXN1A Limited Genetic Variation [225]
CLTC OTBFASMA Limited Genetic Variation [226]
CNTNAP1 OT5Y03EU Limited Biomarker [227]
COIL OTP4I4DL Limited Biomarker [228]
CYP4V2 OTQKNK0D Limited Biomarker [229]
DCTN3 OTQOSUES Limited Genetic Variation [225]
DDX4 OTQOV093 Limited Altered Expression [230]
DDX6 OTKWXVDY Limited Genetic Variation [23]
DERL3 OTRZRT6Q Limited Biomarker [231]
DHX32 OTDYB66V Limited Altered Expression [232]
DNER OT2GH2E5 Limited Biomarker [233]
DNTT OTFSEF12 Limited Biomarker [234]
DYNC1H1 OTD1KRKO Limited Genetic Variation [225]
EIF1AX OTWG2LAB Limited Genetic Variation [235]
EIF3K OTGTKVGO Limited Biomarker [236]
ENO2 OTRODL0T Limited Biomarker [237]
ETV5 OTE2OBM4 Limited Genetic Variation [238]
ETV7 OTIAADPA Limited Biomarker [239]
FCRL5 OTA7VHNE Limited Altered Expression [240]
FRS2 OTDMD800 Limited Biomarker [241]
GH2 OT32TR4C Limited Biomarker [242]
GLIS2 OTOUUV1X Limited Biomarker [243]
HERPUD1 OT9EROL6 Limited Biomarker [37]
HPR OTXSC9UB Limited Altered Expression [244]
HSH2D OTOGB2BR Limited Biomarker [245]
HYAL2 OTTVINXW Limited Altered Expression [246]
INSM1 OTG8RV8E Limited Biomarker [247]
INSM2 OTNMQUZV Limited Biomarker [248]
ISCU OTSW6DQP Limited Biomarker [249]
KDM6A OTZM3MJJ Limited Genetic Variation [250]
KLRD1 OTMYLOV4 Limited Genetic Variation [19]
MAD2L1 OTXNGZCG Limited Biomarker [67]
MARCKSL1 OT13J2FM Limited Biomarker [251]
NDUFAB1 OTF906UR Limited Biomarker [215]
NUTM1 OTONYC08 Limited Genetic Variation [252]
NXF1 OTEFHXG6 Limited Altered Expression [253]
OAS3 OT6E5FYS Limited Genetic Variation [27]
PARP9 OT7K4494 Limited Genetic Variation [89]
PASD1 OTZZWR7L Limited Biomarker [254]
PFDN5 OTTKPTUP Limited Biomarker [25]
PIAS2 OTJLSC3V Limited Genetic Variation [255]
PLEKHA2 OTY2AP6T Limited Biomarker [256]
POU2AF1 OTOO6WHL Limited Genetic Variation [257]
PPP1R3A OTJL9VYP Limited Genetic Variation [258]
PTPRA OTZA82J1 Limited Biomarker [259]
RAD54B OTMWB2P2 Limited Altered Expression [260]
RAG1 OTV131E4 Limited Biomarker [261]
RBL2 OTBQSOE6 Limited Altered Expression [262]
RBP1 OTRP1MFC Limited Biomarker [263]
RCAN1 OT1MVXC7 Limited Biomarker [264]
RHOJ OTWI65OA Limited Biomarker [265]
RIT1 OTVNOGOH Limited Altered Expression [266]
SART3 OTC1AM7S Limited Genetic Variation [27]
SEL1L OTC0FB7T Limited Genetic Variation [267]
SGCE OT9F17JB Limited Altered Expression [268]
SLAMF1 OTBTT3ZQ Limited Altered Expression [269]
SLC16A4 OT1YXBKC Limited Altered Expression [36]
SLC7A4 OTAVC6QS Limited Biomarker [270]
SND1 OTT734JN Limited Genetic Variation [27]
SRI OT4R3EAC Limited Altered Expression [271]
STING1 OTDAP4G0 Limited Biomarker [181]
TELO2 OT2YQ9L8 Limited Biomarker [239]
TLE2 OT2KSZ9B Limited Altered Expression [268]
TLE3 OTR9PH95 Limited Altered Expression [268]
TLE4 OT4QEH6T Limited Altered Expression [268]
TP53BP2 OTOWJ2Y4 Limited Altered Expression [272]
CORO1A OTVAZOHC Disputed Biomarker [273]
EPM2A OTJU4IAG Disputed Altered Expression [274]
LPXN OTUNV3CK Disputed Altered Expression [275]
NT5DC3 OTRHBVM5 Disputed Genetic Variation [51]
POU2F2 OTPV0J0C Disputed Biomarker [45]
RHOH OT1J9SEB Disputed Altered Expression [275]
AHI1 OT8K2YWY moderate Biomarker [276]
BCL11B OT8KKCVJ moderate Biomarker [277]
BCOR OTG013AX moderate Genetic Variation [278]
CCL4 OT6B8P25 moderate Altered Expression [279]
CD247 OT45FGUX moderate Biomarker [280]
CDK2AP2 OTR99SJ8 moderate Altered Expression [281]
CKS1B OTNUPLUJ moderate Biomarker [282]
CLEC10A OTD8HQT6 moderate Biomarker [283]
DCC OT2C1SHW moderate Genetic Variation [284]
DLC1 OTP8LMCR moderate Biomarker [285]
DLEC1 OTMKKBUW moderate Posttranslational Modification [286]
DYNLL1 OTR69LHT moderate Biomarker [287]
ERCC5 OTQAKFJM moderate Genetic Variation [288]
ERVW-1 OTWV8DXJ moderate Biomarker [289]
GNL3 OTILGYO4 moderate Biomarker [290]
IL10RA OTOX3D1D moderate Genetic Variation [291]
IRF5 OT8SIIAP moderate Biomarker [292]
JUNB OTG2JXV5 moderate Biomarker [293]
KIR2DL4 OTXN18OA moderate Biomarker [294]
LAMTOR2 OTHEDISB moderate Altered Expression [281]
LBR OT1HG3HG moderate Biomarker [295]
LGALS7 OTMSVI7R moderate Altered Expression [296]
LXN OTZQ2M6Y moderate Biomarker [297]
NINL OTWIK6HT moderate Biomarker [298]
PLSCR4 OT2AMYLY moderate Genetic Variation [51]
PRF1 OTFVXD7H moderate Genetic Variation [299]
RASGRF1 OTNWJ7EN moderate Biomarker [173]
RPP14 OT4OYFSK moderate Altered Expression [281]
SERPINA5 OTTZXPGD moderate Biomarker [119]
SF3B6 OTPRKS6S moderate Altered Expression [281]
SLPI OTUNFUU8 moderate Biomarker [46]
SOS1 OTTCWXC3 moderate Biomarker [173]
STAT4 OTAK3VFR moderate Altered Expression [300]
TLE1 OT50MRZ1 moderate Biomarker [301]
TLX1 OTVN0MNW moderate Biomarker [302]
TNFRSF6B OTKAN9G7 moderate Altered Expression [303]
TPM3 OT5RU5G6 moderate Biomarker [304]
ABCE1 OTH19LOA Strong Biomarker [305]
ABRAXAS1 OT1K4J80 Strong Genetic Variation [31]
ACOX1 OTM0A0DY Strong Biomarker [306]
ACSF3 OT3WZW8S Strong Genetic Variation [307]
ADAM19 OTH88TXU Strong Genetic Variation [154]
ADGRG7 OT4IPNZC Strong Biomarker [308]
AHRR OTSJ12W6 Strong Biomarker [309]
ANP32B OT3SQMLU Strong Biomarker [42]
ARHGAP24 OTCQCEZS Strong Biomarker [310]
ARID3A OTZZ4SFP Strong Biomarker [311]
ARR3 OTRZ00CH Strong Genetic Variation [72]
ASPG OT5E2EKR Strong Biomarker [312]
ATF2 OTNIZPEA Strong Genetic Variation [313]
ATF7 OTM8T3OD Strong Biomarker [313]
ATF7IP OTU6ZA7F Strong Biomarker [314]
ATMIN OTEADE76 Strong Altered Expression [287]
BCL2L11 OTNQQWFJ Strong Biomarker [315]
BCR OTCN76C1 Strong Biomarker [316]
CACUL1 OT6P1ZVP Strong Biomarker [26]
CARD11 OTRCTLYC Strong Genetic Variation [317]
CBFA2T3 OTOJ10S1 Strong Genetic Variation [307]
CBLL2 OTB4AD3V Strong Altered Expression [109]
CCAR1 OTUXLQZZ Strong Biomarker [161]
CCDC51 OTOJNHNA Strong Biomarker [318]
CCL19 OTQ2UJMH Strong Biomarker [319]
CD2AP OTC76KQM Strong Biomarker [320]
CD48 OT83ZNPP Strong Biomarker [321]
CDC42BPB OTO6NT7Q Strong Genetic Variation [322]
CDCA7 OT12HDZY Strong Biomarker [323]
CFDP1 OTXY7J96 Strong Altered Expression [324]
CFL1 OTT6D5MH Strong Biomarker [66]
CHD1 OT9R9G0H Strong Genetic Variation [325]
CIB1 OT4BVCRU Strong Biomarker [55]
CLEC4D OTT7X1UC Strong Altered Expression [326]
CLTA OTLHOXMQ Strong Biomarker [68]
CMTM1 OTKN7E89 Strong Biomarker [327]
CNOT2 OT98OJ42 Strong Genetic Variation [328]
CREBZF OTO3TOEU Strong Genetic Variation [329]
CXADR OT9ZP02A Strong Genetic Variation [72]
DCLRE1C OTW3KB1I Strong Biomarker [330]
DDIT3 OTI8YKKE Strong Genetic Variation [331]
DDX53 OTHK3EGZ Strong Genetic Variation [332]
DIXDC1 OT87DXEG Strong Biomarker [333]
DLX5 OTEEFBEU Strong Biomarker [334]
DOHH OTDRAT3F Strong Biomarker [335]
E2F8 OTQKZGFP Strong Biomarker [336]
EEF1E1 OTRA6XOB Strong Biomarker [66]
EGR3 OTGPJIRA Strong Altered Expression [337]
EIF4A1 OTMTBX6N Strong Biomarker [338]
EIF4A2 OT08H03R Strong Biomarker [338]
EIF4G2 OTEO98CR Strong Altered Expression [324]
EIF6 OTEXMUED Strong Biomarker [339]
ELF4 OT167PR5 Strong Altered Expression [340]
ENOSF1 OT65D3ZK Strong Biomarker [341]
FAM72A OTBZYSR3 Strong Genetic Variation [342]
FAM72B OT6AOG64 Strong Genetic Variation [342]
FGF6 OTRJ679P Strong Biomarker [343]
FIP1L1 OTF91GTL Strong Biomarker [344]
FMOD OT9EJ5H8 Strong Biomarker [345]
FOXO4 OT90X9LN Strong Biomarker [346]
FOXP2 OTVX6A59 Strong Biomarker [347]
GCSAM OTZNOPYK Strong Biomarker [348]
GEMIN4 OTX7402E Strong Altered Expression [324]
GFI1 OT9HB9H8 Strong Biomarker [349]
GKN1 OT7ZYFQ9 Strong Biomarker [350]
GNA13 OTVDL515 Strong Biomarker [351]
GOT2 OT6XBWN0 Strong Altered Expression [352]
GPR65 OTCF5O4G Strong Biomarker [353]
H2AX OT18UX57 Strong Biomarker [354]
H4C1 OTB71W46 Strong Genetic Variation [355]
HACE1 OTEZULKD Strong Altered Expression [356]
HBZ OTMHGFSS Strong Altered Expression [357]
HCST OTILCB4K Strong Biomarker [358]
HS3ST2 OTWFA0GJ Strong Biomarker [343]
HSPA1L OTC2V1K6 Strong Biomarker [359]
HSPH1 OTVRR73T Strong Altered Expression [335]
HVCN1 OT4ALYU4 Strong Genetic Variation [360]
IBTK OTB2GM4G Strong Biomarker [361]
ICAM3 OTTZ5A5D Strong Genetic Variation [154]
IL12RB1 OTM1IJO2 Strong Genetic Variation [179]
IL17RB OT0KDNSF Strong Biomarker [362]
IL9R OTILCLXA Strong Altered Expression [363]
INAFM2 OT2H4HAP Strong Biomarker [364]
IRF4 OT1DHQ1P Strong Altered Expression [365]
IRF7 OTC1A2PQ Strong Biomarker [366]
ISG20 OTCWRJJW Strong Biomarker [367]
ISL1 OTVNVKAX Strong Altered Expression [368]
ITM2B OTMXEPXB Strong Biomarker [369]
KCNRG OTXHYFOD Strong Altered Expression [370]
KIR3DL1 OTPOSXFX Strong Genetic Variation [371]
KLHDC8B OTKP6LCR Strong Biomarker [372]
KMT2D OTTVHCLY Strong Altered Expression [373]
KRT20 OT4RB40L Strong Biomarker [134]
KRT222 OTTK7M0R Strong Biomarker [374]
LAMTOR1 OTIBJBW9 Strong Biomarker [66]
LNX2 OT3I0A91 Strong Genetic Variation [322]
LRP12 OTRT1UJ7 Strong Posttranslational Modification [375]
MAFK OTZJUE4P Strong Biomarker [66]
MAGT1 OTQSAV5C Strong Biomarker [18]
MEF2B OT880SE6 Strong Genetic Variation [376]
MLKL OTDSLC81 Strong Altered Expression [377]
MSH6 OT46FP09 Strong Genetic Variation [378]
MTG1 OTC9U1LI Strong Genetic Variation [188]
MTSS1 OT5DTDO2 Strong Biomarker [379]
MUL1 OT2JC9YR Strong Altered Expression [109]
MYDGF OT9HRPL6 Strong Biomarker [362]
MYH14 OT1TZEJK Strong Biomarker [348]
NCR3 OT20M764 Strong Biomarker [380]
NCR3LG1 OT15YWU7 Strong Altered Expression [381]
NFE2L3 OT1MGXT0 Strong Biomarker [382]
NOCT OTVSYP2D Strong Genetic Variation [383]
NOMO1 OTIALEI1 Strong Genetic Variation [384]
ODF1 OTTSURLA Strong Altered Expression [385]
P3H3 OTRC8QCM Strong Altered Expression [386]
PDLIM7 OTAZVODU Strong Biomarker [387]
PER2 OTU2B1DJ Strong Genetic Variation [388]
PHB2 OTCAX3AW Strong Altered Expression [389]
PHLPP1 OTIFXW8D Strong Altered Expression [390]
PIGK OTAFSYLD Strong Altered Expression [391]
PKNOX1 OTUDMNHX Strong Genetic Variation [392]
PLEKHO1 OTMVUQ9W Strong Altered Expression [393]
POLE3 OTOELRF6 Strong Genetic Variation [342]
PPP1R15A OTYG179K Strong Biomarker [394]
PRC1 OTHD0XS0 Strong Biomarker [395]
PRDM1 OTQLSVBS Strong Biomarker [57]
PRKN OTJBN41W Strong Altered Expression [109]
PSMD2 OT6HZHN7 Strong Altered Expression [324]
PWWP3A OTXQVL4U Strong Altered Expression [396]
RAB7B OT60A0E9 Strong Altered Expression [159]
RAD23B OT0PGOG3 Strong Altered Expression [109]
RAE1 OT54OKC3 Strong Biomarker [397]
RAG2 OTG9UYTW Strong Biomarker [398]
RASGRP1 OTX9WN2E Strong Biomarker [18]
RCOR1 OTREADPC Strong Biomarker [399]
RECQL4 OT59LSW7 Strong Biomarker [341]
RFC1 OT3L5PK3 Strong Genetic Variation [400]
RNASE7 OTIXO0Z4 Strong Biomarker [397]
RNF2 OTFPLOIN Strong Altered Expression [395]
RTEL1 OTI3PJCT Strong Biomarker [316]
RTL10 OTHGB81W Strong Biomarker [401]
SETD3 OTO5RAU2 Strong Altered Expression [402]
SETX OTG3JNOQ Strong Biomarker [403]
SH3BP4 OTVIRKW7 Strong Biomarker [404]
SMAD5 OTQNSVCQ Strong Biomarker [405]
SMARCAL1 OTTKXLUZ Strong Altered Expression [406]
SMC3 OTWGFRHD Strong Biomarker [315]
SMCHD1 OTBV52DR Strong Altered Expression [407]
SNRPN OTQB1ID1 Strong Biomarker [343]
SOAT1 OTB4Y5RJ Strong Biomarker [352]
SPART OTIVOS2I Strong Biomarker [408]
SPATA2 OTOA45GL Strong Biomarker [358]
SPG7 OT8OY9ST Strong Genetic Variation [72]
SPIB OTO4YKYI Strong Altered Expression [409]
SSB OTCCTPBR Strong Genetic Variation [410]
SSX2 OT2Z6RLL Strong Genetic Variation [411]
STAT2 OTO9G2RZ Strong Biomarker [321]
STAT5A OTBSJGN3 Strong Biomarker [412]
STAT5B OTZVPEBT Strong Biomarker [412]
STXBP2 OTX8GUC4 Strong Biomarker [413]
SUB1 OTK71JYU Strong Altered Expression [281]
TCL1B OT4CSO39 Strong Biomarker [171]
TCP1 OT1MGUX9 Strong Biomarker [414]
TFG OT2KJENI Strong Biomarker [308]
TIGAR OTR7NMRJ Strong Altered Expression [357]
TINF2 OT861N2N Strong Biomarker [172]
TJP1 OTBDCUPK Strong Biomarker [415]
TLX2 OTPFAUM8 Strong Biomarker [416]
TMEM176A OTOZDWXX Strong Altered Expression [417]
TMTC3 OTMTTDYG Strong Genetic Variation [329]
TNFRSF10C OTVHOL9B Strong Posttranslational Modification [418]
TNFSF8 OTDYGDJ3 Strong Biomarker [419]
TP53INP2 OT0GTBXO Strong Altered Expression [391]
TP73 OT0LUO47 Strong Biomarker [310]
TPPP2 OTI3WA6X Strong Biomarker [66]
TRAF1 OTTLM5RU Strong Biomarker [420]
TRAF3 OT5TQBGV Strong Biomarker [421]
TREX1 OTQG7K12 Strong Genetic Variation [422]
TRIM13 OTQIUACB Strong Genetic Variation [72]
TRIM65 OTSQTK3A Strong Biomarker [423]
TRRAP OT68OI2Y Strong Biomarker [424]
AIRE OTA7G1Y1 Definitive Biomarker [425]
BLNK OTSSPF6F Definitive Biomarker [426]
CAMLG OTTSRY39 Definitive Altered Expression [427]
FCRL4 OT3DVTRV Definitive Altered Expression [428]
GNA12 OT3IRZH3 Definitive Altered Expression [429]
GNLY OTZJKA8C Definitive Biomarker [430]
LYL1 OTCNOV1M Definitive Biomarker [431]
MIXL1 OT584VOQ Definitive Altered Expression [432]
NSF OTKRJ2ZT Definitive Biomarker [433]
PALB2 OT6DNDBG Definitive Biomarker [434]
PIMREG OTKC8T3E Definitive Altered Expression [435]
RBM14 OTO9GMBD Definitive Genetic Variation [436]
RC3H1 OTCU6CYA Definitive Biomarker [425]
RGS1 OTGXJYMG Definitive Altered Expression [437]
RGS13 OTPAMQ18 Definitive Altered Expression [437]
RPL22 OTVCN8K0 Definitive Biomarker [438]
RRBP1 OT4ZTPTM Definitive Biomarker [439]
SERPINA9 OT0OIZH1 Definitive Altered Expression [440]
------------------------------------------------------------------------------------
⏷ Show the Full List of 323 DOT(s)

References

1 Expression and modulation of annexin VIII in human leukemia-lymphoma cell lines.Leuk Res. 1993 Nov;17(11):949-57. doi: 10.1016/0145-2126(93)90042-j.
2 Mitochondrial hypoxic stress induces widespread RNA editing by APOBEC3G in natural killer cells.Genome Biol. 2019 Feb 21;20(1):37. doi: 10.1186/s13059-019-1651-1.
3 Molecular cloning, structural modeling and production of recombinant Aspergillus terreusl. asparaginase in Escherichia coli.Int J Biol Macromol. 2018 Jan;106:1041-1051. doi: 10.1016/j.ijbiomac.2017.08.110. Epub 2017 Aug 26.
4 Tumor suppressors BTG1 and BTG2: Beyond growth control.J Cell Physiol. 2019 May;234(5):5379-5389. doi: 10.1002/jcp.27407. Epub 2018 Oct 23.
5 hBUB1 defects in leukemia and lymphoma cells.Oncogene. 2002 Jul 11;21(30):4673-9. doi: 10.1038/sj.onc.1205585.
6 Frameshift mutations in caspase-5 and other target genes in leukemia and lymphoma cell lines having microsatellite instability.Leuk Res. 2003 Apr;27(4):359-61. doi: 10.1016/s0145-2126(02)00215-1.
7 Development of specific nanobodies (VHH) for CD19 immuno-targeting of human B-lymphocytes.Iran J Basic Med Sci. 2018 May;21(5):455-464. doi: 10.22038/IJBMS.2018.26778.6557.
8 Distinct breakpoints in band 11q23 of the t(4;11) and t(11;14) associated with leukocyte malignancy.Genes Chromosomes Cancer. 1992 Jul;5(1):50-6. doi: 10.1002/gcc.2870050108.
9 cdc25 cell cycle-activating phosphatases and c-myc expression in human non-Hodgkin's lymphomas.Cancer Res. 1998 Apr 15;58(8):1762-7.
10 Expression of cholesteryl ester transfer protein (CETP) in germinal centre B cells and their neoplastic counterparts.Histopathology. 2004 Jul;45(1):73-81. doi: 10.1111/j.1365-2559.2004.01905.x.
11 Biomarker Dynamics in B-cell Lymphoma: A Longitudinal Prospective Study of Plasma Samples Up to 25 Years before Diagnosis.Cancer Res. 2017 Mar 15;77(6):1408-1415. doi: 10.1158/0008-5472.CAN-16-2345. Epub 2017 Jan 20.
12 Alterations of the cyclin-dependent kinase inhibitor p19 (INK4D) is rare in hematopoietic malignancies.Leukemia. 1996 Dec;10(12):1897-900.
13 Epstein-Barr virus-related lymphomagenesis in a child with Wiskott-Aldrich syndrome.Hematol Oncol. 1993 May-Jun;11(3):139-45. doi: 10.1002/hon.2900110304.
14 Expression of truncated transcripts of the proto-oncogene c-fps/fes in human lymphoma and lymphoid leukemia cell lines.Oncogene. 1992 May;7(5):943-52.
15 Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells.J Biol Chem. 1995 Jan 13;270(2):815-22. doi: 10.1074/jbc.270.2.815.
16 Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin.Hum Pathol. 2000 Feb;31(2):263-8. doi: 10.1016/s0046-8177(00)80233-6.
17 Medical conditions in Ashkenazi schizophrenic pedigrees.Schizophr Bull. 1994;20(3):507-17. doi: 10.1093/schbul/20.3.507.
18 Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases.Immunol Rev. 2019 Sep;291(1):174-189. doi: 10.1111/imr.12791.
19 A case of lymphoblastoid natural killer (NK)-cell lymphoma: association with the NK-cell receptor complex CD94/NKG2 and TP53 intragenic deletion.Br J Dermatol. 2002 Jan;146(1):148-53. doi: 10.1046/j.0007-0963.2001.04571.x.
20 Localization of a lymphocyte-specific protein tyrosine kinase gene (lck) at a site of frequent chromosomal abnormalities in human lymphomas.Proc Natl Acad Sci U S A. 1986 Oct;83(19):7400-4. doi: 10.1073/pnas.83.19.7400.
21 The p54 cleaved form of the tyrosine kinase Lyn generated by caspases during BCR-induced cell death in B lymphoma acts as a negative regulator of apoptosis.FASEB J. 2003 Apr;17(6):711-3. doi: 10.1096/fj.02-0716fje. Epub 2003 Feb 5.
22 Mutations in the mitotic check point gene, MAD1L1, in human cancers.Oncogene. 2001 May 31;20(25):3301-5. doi: 10.1038/sj.onc.1204421.
23 Cloning and expression of a murine cDNA homologous to the human RCK/P54, a lymphoma-linked chromosomal translocation junction gene on 11q23.Gene. 1995 Dec 12;166(2):293-6. doi: 10.1016/0378-1119(95)00559-5.
24 Expression of thrombopoietin and thrombopoietin receptor MPL in human leukemia-lymphoma and solid tumor cell lines.Leuk Res. 1996 Oct;20(10):831-8. doi: 10.1016/s0145-2126(96)00057-4.
25 MM-1, a c-Myc-binding protein, is a candidate for a tumor suppressor in leukemia/lymphoma and tongue cancer.J Biol Chem. 2001 Nov 30;276(48):45137-44. doi: 10.1074/jbc.M106127200. Epub 2001 Sep 20.
26 CRL4(DCAF2) negatively regulates IL-23 production in dendritic cells and limits the development of psoriasis.J Exp Med. 2018 Aug 6;215(8):1999-2017. doi: 10.1084/jem.20180210. Epub 2018 Jul 17.
27 Transcriptional regulatory effects of lymphoma-associated NFKB2/lyt10 protooncogenes.Oncogene. 2000 Mar 2;19(10):1334-45. doi: 10.1038/sj.onc.1203432.
28 Prolactin and the immune system.Immunomethods. 1994 Aug;5(1):21-30. doi: 10.1006/immu.1994.1034.
29 Rearrangement of the T-cell receptor delta chain gene in T-cell lymphomas with a mature phenotype.Am J Pathol. 1991 Jul;139(1):161-8.
30 Chemoattractant receptor-homologous molecule expressed on Th2 cells activation in vivo increases blood leukocyte counts and its blockade abrogates 13,14-dihydro-15-keto-prostaglandin D2-induced eosinophilia in rats.J Pharmacol Exp Ther. 2003 Nov;307(2):518-25. doi: 10.1124/jpet.103.055442. Epub 2003 Sep 15.
31 Kaposi Sarcoma in Association With an Extracavitary Primary Effusion Lymphoma Showing Unusual Intravascular Involvement: Report of a Case Harboring a FAM175A Germline Mutation.Am J Dermatopathol. 2020 Jan;42(1):55-60. doi: 10.1097/DAD.0000000000001491.
32 ROR1 associates unfavorable prognosis and promotes lymphoma growth in DLBCL by affecting PI3K/Akt/mTOR signaling pathway.Biofactors. 2019 May;45(3):416-426. doi: 10.1002/biof.1498. Epub 2019 Feb 24.
33 Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).Nat Biotechnol. 2000 Nov;18(11):1185-90. doi: 10.1038/81183.
34 p38 and JNK pathways control E-selectin-dependent extravasation of colon cancer cells by modulating miR-31 transcription.Oncotarget. 2017 Jan 3;8(1):1678-1687. doi: 10.18632/oncotarget.13779.
35 Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate.Orphanet J Rare Dis. 2019 Mar 13;14(1):65. doi: 10.1186/s13023-019-1043-3.
36 Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma.Haematologica. 2017 Jul;102(7):1247-1257. doi: 10.3324/haematol.2016.163030. Epub 2017 Apr 6.
37 Chemical evaluation and cytotoxic mechanism investigation of Clinacanthus nutans extract in lymphoma SUP-T1 cells.Environ Toxicol. 2018 Dec;33(12):1229-1236. doi: 10.1002/tox.22629. Epub 2018 Sep 6.
38 Pulmonary malignant lymphoma of mucosa-associated lymphoid tissue (MALT) arising in a pediatric HIV-positive patient.Am J Surg Pathol. 1995 Mar;19(3):357-63. doi: 10.1097/00000478-199503000-00014.
39 Stabilin-1 is expressed in human breast cancer and supports tumor growth in mammary adenocarcinoma mouse model. Oncotarget. 2016 May 24;7(21):31097-110.
40 A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.Leukemia. 2017 Jul;31(7):1611-1621. doi: 10.1038/leu.2016.352. Epub 2017 Nov 28.
41 Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.Hum Gene Ther. 2018 May;29(5):585-601. doi: 10.1089/hum.2018.001.
42 Systemic lupus erythematosus and lymphoma: Incidence, pathogenesis and biology.Leuk Res. 2018 Dec;75:45-49. doi: 10.1016/j.leukres.2018.11.004. Epub 2018 Nov 12.
43 Truncated TSG101 transcripts in human leukemia and lymphoma cell lines.J Cancer Res Clin Oncol. 2000 Feb;126(2):79-84.
44 Study of the efficacy of a pronucleotide of 2-chloro-2'-deoxyadenosine in deoxycytidine kinase-deficient lymphoma cells.Nucleosides Nucleotides Nucleic Acids. 2006;25(9-11):997-1000. doi: 10.1080/15257770600889444.
45 Oct transcription factors mediate t(14;18) lymphoma cell survival by directly regulating bcl-2 expression.Oncogene. 2006 Feb 9;25(6):888-98. doi: 10.1038/sj.onc.1209127.
46 Cutaneous anaplastic large-cell lymphoma should be evaluated for systemic involvement regardless of ALK-1 status: case reports and review of literature.Am J Clin Dermatol. 2011 Jun 1;12(3):203-9. doi: 10.2165/11537520-000000000-00000.
47 High-resolution genomic profiling reveals clonal evolution and competition in gastrointestinal marginal zone B-cell lymphoma and its large cell variant.Int J Cancer. 2013 Feb 1;132(3):E116-27. doi: 10.1002/ijc.27774. Epub 2012 Sep 1.
48 The novel double-hit, t(8;22)(q24;q11)/MYC-IGL and t(14;15)(q32;q24)/IGH-BCL2A1, in diffuse large B-cell lymphoma.Cancer Genet. 2017 Aug;214-215:26-31. doi: 10.1016/j.cancergen.2017.03.009. Epub 2017 Apr 4.
49 Increased T-cell activation and Th1 cytokine concentrations prior to the diagnosis of B-cell lymphoma in HIV infected patients.J Clin Immunol. 2013 Jan;33(1):22-9. doi: 10.1007/s10875-012-9766-0. Epub 2012 Aug 23.
50 Expression and phosphorylation of eukaryotic translation initiation factor 4E binding protein 1 in B-cell lymphomas and reactive lymphoid tissues.Arch Pathol Lab Med. 2011 Mar;135(3):365-71. doi: 10.5858/2009-0759-OA.1.
51 The common viral insertion site Evi12 is located in the 5'-noncoding region of Gnn, a novel gene with enhanced expression in two subclasses of human acute myeloid leukemia.J Virol. 2005 May;79(9):5249-58. doi: 10.1128/JVI.79.9.5249-5258.2005.
52 Joint effect between regular use of non-steroidal anti-inflammatory drugs, variants in inflammatory genes and risk of lymphoma.Cancer Causes Control. 2008 Mar;19(2):163-73. doi: 10.1007/s10552-007-9082-9. Epub 2007 Nov 24.
53 Dual enhancement of T and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival.Sci Signal. 2017 Oct 10;10(500):eaam5353. doi: 10.1126/scisignal.aam5353.
54 Identification of Pax5 as a target of MTA1 in B-cell lymphomas.Cancer Res. 2007 Aug 1;67(15):7132-8. doi: 10.1158/0008-5472.CAN-07-0750.
55 Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.Cancer Res. 2009 Jan 15;69(2):547-53. doi: 10.1158/0008-5472.CAN-08-2968.
56 Recent Advances in the Function of the 67 kDa Laminin Receptor and its Targeting for Personalized Therapy in Cancer.Curr Pharm Des. 2017;23(32):4745-4757. doi: 10.2174/1381612823666170710125332.
57 HSP70-Hrd1 axis precludes the oncorepressor potential of N-terminal misfolded Blimp-1s in lymphoma cells.Nat Commun. 2017 Aug 25;8(1):363. doi: 10.1038/s41467-017-00476-w.
58 Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas.Ann Hematol. 2014 Feb;93(2):243-7. doi: 10.1007/s00277-013-1864-4.
59 Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells.Cell. 2016 Oct 6;167(2):405-418.e13. doi: 10.1016/j.cell.2016.08.032. Epub 2016 Sep 29.
60 Respiratory uncoupling in skeletal muscle delays death and diminishes age-related disease.Cell Metab. 2007 Dec;6(6):497-505. doi: 10.1016/j.cmet.2007.10.010.
61 Influence of polymorphisms in ERCC5, XPA and MTR DNA repair and synthesis genes in B-cell lymphoma risk. A case-control study in Spanish population.J BUON. 2013 Apr-Jun;18(2):486-90.
62 ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells.Blood. 2007 Mar 1;109(5):2032-9. doi: 10.1182/blood-2006-03-011759. Epub 2006 Oct 12.
63 Phosphatidylinositol 3-kinase blockade increases genomic instability in B cells.Nature. 2017 Feb 23;542(7642):489-493. doi: 10.1038/nature21406. Epub 2017 Feb 15.
64 ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway.Nat Cell Biol. 2019 May;21(5):579-591. doi: 10.1038/s41556-019-0305-6. Epub 2019 Apr 8.
65 Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities.Leukemia. 2014 Jul;28(7):1414-22. doi: 10.1038/leu.2014.56. Epub 2014 Feb 3.
66 Analysis of the novel cyclin-dependent kinase 4 and 6 inhibitor gene p18 in lymphoma and leukemia cell lines.Leuk Res. 1996 Feb;20(2):197-200. doi: 10.1016/0145-2126(95)00137-9.
67 Mitotic slippage: an old tale with a new twist.Cell Cycle. 2019 Jan;18(1):7-15. doi: 10.1080/15384101.2018.1559557. Epub 2019 Jan 2.
68 Cutaneous spindled follicle center cell lymphoma with abundant mucin: A diagnostic pitfall.J Cutan Pathol. 2020 Apr;47(4):394-397. doi: 10.1111/cup.13609. Epub 2019 Nov 27.
69 Selective expansion of marginal zone B cells in Emicro-API2-MALT1 mice is linked to enhanced IkappaB kinase gamma polyubiquitination.Cancer Res. 2006 May 15;66(10):5270-7. doi: 10.1158/0008-5472.CAN-05-4590.
70 Systematic Multiomics Analysis of Alterations in C1QBP mRNA Expression and Relevance for Clinical Outcomes in Cancers.J Clin Med. 2019 Apr 15;8(4):513. doi: 10.3390/jcm8040513.
71 Induction of apoptosis in E-myc lymphoma cells in vitro and in vivo through calpain inhibition.Exp Hematol. 2012 Jul;40(7):548-563.e2. doi: 10.1016/j.exphem.2012.02.002. Epub 2012 Feb 23.
72 Challenges of driving CD30-directed CAR-T cells to the clinic.BMC Cancer. 2019 Mar 6;19(1):203. doi: 10.1186/s12885-019-5415-9.
73 Oncogenic role of the chromobox protein CBX7 in gastric cancer.J Exp Clin Cancer Res. 2010 Aug 19;29(1):114. doi: 10.1186/1756-9966-29-114.
74 Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A.Leukemia. 2000 May;14(5):898-904. doi: 10.1038/sj.leu.2401761.
75 Early and late hematologic toxicity following CD19 CAR-T cells.Bone Marrow Transplant. 2019 Oct;54(10):1643-1650. doi: 10.1038/s41409-019-0487-3. Epub 2019 Feb 26.
76 During acute graft versus host disease CD28 deletion in donor CD8(+) , but not CD4(+) , Tcells maintain antileukemia responses in mice.Eur J Immunol. 2018 Dec;48(12):2055-2067. doi: 10.1002/eji.201847669. Epub 2018 Nov 14.
77 Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.Int J Mol Sci. 2017 Oct 27;18(11):2259. doi: 10.3390/ijms18112259.
78 High frequency of inactivating tetraspanin C D37 mutations in diffuse large B-cell lymphoma at immune-privileged sites.Blood. 2019 Sep 19;134(12):946-950. doi: 10.1182/blood.2019001185. Epub 2019 Jul 31.
79 Augmentation of Saporin-Based Immunotoxins for Human Leukaemia and Lymphoma Cells by Triterpenoid Saponins: The Modifying Effects of Small Molecule Pharmacological Agents.Toxins (Basel). 2019 Feb 20;11(2):127. doi: 10.3390/toxins11020127.
80 RIP1 has a role in CD40-mediated apoptosis in human follicular lymphoma cells.Immunobiology. 2017 Nov;222(11):998-1003. doi: 10.1016/j.imbio.2017.06.001. Epub 2017 Jun 10.
81 CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response.Cancer Cell. 2019 Mar 18;35(3):473-488.e6. doi: 10.1016/j.ccell.2019.02.006.
82 CD47/SIRP blocking enhances CD19/CD3-bispecific T cell engager antibody-mediated lysis of B cell malignancies.Biochem Biophys Res Commun. 2019 Feb 12;509(3):739-745. doi: 10.1016/j.bbrc.2018.12.175. Epub 2019 Jan 3.
83 CD74 interferes with the expression of fas receptor on the surface of lymphoma cells.J Exp Clin Cancer Res. 2014 Oct 10;33(1):80. doi: 10.1186/s13046-014-0080-y.
84 CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential.Eur J Haematol. 2019 Feb;102(2):191-196. doi: 10.1111/ejh.13191. Epub 2018 Nov 23.
85 Evaluation of costimulatory molecules in dogs with B cell high grade lymphoma.PLoS One. 2018 Jul 24;13(7):e0201222. doi: 10.1371/journal.pone.0201222. eCollection 2018.
86 Study on the role of G1 cyclins in Epstein-Barr virus-associated human lymphomas maintained in severe combined immune deficiency (SCID) mice.Int J Cancer. 2001 Apr 15;92(2):232-9. doi: 10.1002/1097-0215(200102)9999:9999<::aid-ijc1171>3.0.co;2-r.
87 Hedyotisdiffusa Willd inhibits proliferation and induces apoptosis of 5FU resistant colorectal cancer cells by regulating the PI3K/AKT signaling pathway.Mol Med Rep. 2018 Jan;17(1):358-365. doi: 10.3892/mmr.2017.7903. Epub 2017 Oct 26.
88 Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma.Sci Rep. 2019 May 10;9(1):7193. doi: 10.1038/s41598-019-43760-z.
89 A case-report of a pulmonary tuberculosis with lymphadenopathy mimicking a lymphoma.Int J Infect Dis. 2018 May;70:38-41. doi: 10.1016/j.ijid.2018.02.011. Epub 2018 Mar 1.
90 DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas.Mol Cancer Ther. 2019 Jul;18(7):1255-1264. doi: 10.1158/1535-7163.MCT-18-0919. Epub 2019 May 7.
91 Clinicopathological analysis of 46 cases with CD4(+) and/or CD56(+) immature haematolymphoid malignancy: reappraisal of blastic plasmacytoid dendritic cell and related neoplasms.Histopathology. 2017 Dec;71(6):972-984. doi: 10.1111/his.13340. Epub 2017 Oct 10.
92 Detection of Tax-specific CTLs in lymph nodes of adult T-cell leukemia/lymphoma patients and its association with Foxp3 positivity of regulatory T-cell function.Oncol Lett. 2017 Jun;13(6):4611-4618. doi: 10.3892/ol.2017.6067. Epub 2017 Apr 21.
93 The CREB Coactivator CRTC2 Is a Lymphoma Tumor Suppressor that Preserves Genome Integrity through Transcription of DNA Mismatch Repair Genes.Cell Rep. 2015 Jun 9;11(9):1350-7. doi: 10.1016/j.celrep.2015.04.052. Epub 2015 May 21.
94 CSF1R Protein Expression in Reactive Lymphoid Tissues and Lymphoma: Its Relevance in Classical Hodgkin Lymphoma.PLoS One. 2015 Jun 12;10(6):e0125203. doi: 10.1371/journal.pone.0125203. eCollection 2015.
95 Lentivirus-mediated down-regulation of CK2 inhibits proliferation and induces apoptosis of malignant lymphoma and leukemia cells.Biochem Cell Biol. 2018 Dec;96(6):786-796. doi: 10.1139/bcb-2017-0345. Epub 2018 May 17.
96 Diacylglycerol Kinase Limits Cytokine-dependent Expansion of CD8(+) T Cells with Broad Antitumor Capacity.EBioMedicine. 2017 May;19:39-48. doi: 10.1016/j.ebiom.2017.04.024. Epub 2017 Apr 14.
97 Regulation of EBV LMP1-triggered EphA4 downregulation in EBV-associated B lymphoma and its impact on patients' survival.Blood. 2016 Sep 22;128(12):1578-89. doi: 10.1182/blood-2016-02-702530. Epub 2016 Jun 23.
98 Functional genomics lead to new therapies in follicular lymphoma.Ann N Y Acad Sci. 2013 Jul;1293:18-24. doi: 10.1111/nyas.12120. Epub 2013 May 15.
99 JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide.Sci Rep. 2017 Aug 7;7(1):7433. doi: 10.1038/s41598-017-07964-5.
100 High coagulation factor VIII and von Willebrand factor in patients with lymphoma and leukemia.Int J Hematol. 2016 Feb;103(2):189-95. doi: 10.1007/s12185-015-1913-y. Epub 2015 Nov 26.
101 EBV lymphoproliferative-associated disease and primary cardiac T-cell lymphoma in a STK4 deficient patient: A case report.Medicine (Baltimore). 2017 Dec;96(48):e8852. doi: 10.1097/MD.0000000000008852.
102 PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.Blood. 2019 May 30;133(22):2401-2412. doi: 10.1182/blood.2018889931. Epub 2019 Apr 11.
103 UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma.Blood. 2016 Mar 24;127(12):1564-74. doi: 10.1182/blood-2015-07-656678. Epub 2015 Dec 23.
104 Efficient transduction of murine B lymphocytes and B lymphoma lines by modified adenoviral vectors: enhancement via targeting to FcR and heparan-containing proteins.Gene Ther. 2001 Jun;8(12):938-45. doi: 10.1038/sj.gt.3301487.
105 t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth.Blood. 2012 Nov 8;120(19):3949-57. doi: 10.1182/blood-2011-11-389908. Epub 2012 Sep 10.
106 Interplay between HGAL and Grb2 proteins regulates B-cell receptor signaling.Blood Adv. 2019 Aug 13;3(15):2286-2297. doi: 10.1182/bloodadvances.2018016162.
107 Small-Molecule Inhibition of PD-1 Transcription Is an Effective Alternative to Antibody Blockade in Cancer Therapy.Cancer Res. 2018 Feb 1;78(3):706-717. doi: 10.1158/0008-5472.CAN-17-0491. Epub 2017 Oct 20.
108 Expression of granzyme B sensitizes ALK+ ALCL tumour cells to apoptosis-inducing drugs.Mol Cancer. 2014 Aug 29;13:199. doi: 10.1186/1476-4598-13-199.
109 Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.J Pathol. 2018 Oct;246(2):141-153. doi: 10.1002/path.5108. Epub 2018 Aug 20.
110 The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma.Cell Death Dis. 2015 Feb 12;6(2):e1635. doi: 10.1038/cddis.2014.594.
111 Correction: Predictive biomarkers for disease sensitivity in lymphoma - the holy grail for HDAC inhibitors?.Oncotarget. 2019 Feb 26;10(17):1661. doi: 10.18632/oncotarget.26767. eCollection 2019 Feb 26.
112 Coexpression of B-lymphoma Moloney murine leukemia virus insertion region-1 and sex-determining region of Y chromosome-related high mobility group box-2 in cervical carcinogenesis.Hum Pathol. 2013 Feb;44(2):208-17. doi: 10.1016/j.humpath.2012.02.020. Epub 2012 Aug 3.
113 The heparanase inhibitor PG545 is a potent anti-lymphoma drug: Mode of action.Matrix Biol. 2019 Apr;77:58-72. doi: 10.1016/j.matbio.2018.08.005. Epub 2018 Aug 7.
114 Ganetespib synergizes with cyclophosphamide to improve survival of mice with autochthonous tumors in a mutant p53-dependent manner.Cell Death Dis. 2017 Mar 16;8(3):e2683. doi: 10.1038/cddis.2017.108.
115 HSPB8 is methylated in hematopoietic malignancies and overexpression of HSPB8 exhibits antileukemia effect.Exp Hematol. 2012 Jan;40(1):14-21. doi: 10.1016/j.exphem.2011.09.004. Epub 2011 Sep 10.
116 Growth-inhibition of cell lines derived from B cell lymphomas through antagonism of serotonin receptor signaling.Sci Rep. 2019 Mar 12;9(1):4276. doi: 10.1038/s41598-019-40825-x.
117 Chromosome analyses in chronic lymphocytic leukemia and related B-cell neoplasms.Cancer Genet Cytogenet. 1991 Aug;55(1):49-56. doi: 10.1016/0165-4608(91)90234-l.
118 Absence of Grail promotes CD8(+) T cell anti-tumour activity.Nat Commun. 2017 Aug 10;8(1):239. doi: 10.1038/s41467-017-00252-w.
119 The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.Blood. 2012 Mar 15;119(11):2590-4. doi: 10.1182/blood-2011-11-390989. Epub 2012 Jan 25.
120 Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma.Oncotarget. 2016 Jun 7;7(23):34201-16. doi: 10.18632/oncotarget.9077.
121 JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia. 2014 Feb;28(2):338-48. doi: 10.1038/leu.2013.157. Epub 2013 May 21.
122 Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth.Nature. 2018 Aug;560(7717):253-257. doi: 10.1038/s41586-018-0387-5. Epub 2018 Aug 1.
123 Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma.Blood. 2010 May 13;115(19):3960-5. doi: 10.1182/blood-2009-10-250134. Epub 2010 Mar 5.
124 Ongoing monoclonal B-cell proliferation is not common in gastric B-cell lymphoma after combined radiochemotherapy.J Clin Oncol. 2004 Aug 1;22(15):3039-45. doi: 10.1200/JCO.2004.08.177.
125 High intratumoural galectin-1 expression predicts adverse outcome in ALK(-) ALCL and CD30(+) PTCL-NOS.Hematol Oncol. 2020 Feb;38(1):59-66. doi: 10.1002/hon.2702. Epub 2020 Jan 1.
126 Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era.AIDS. 2017 Nov 28;31(18):2493-2501. doi: 10.1097/QAD.0000000000001652.
127 Post-translational Modifications of the CARMA1-BCL10-MALT1 Complex in Lymphocytes and Activated B-Cell Like Subtype of Diffuse Large B-Cell Lymphoma.Front Oncol. 2018 Nov 9;8:498. doi: 10.3389/fonc.2018.00498. eCollection 2018.
128 Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy.Lancet. 2001 Jan 6;357(9249):39-40. doi: 10.1016/S0140-6736(00)03571-6.
129 Novel phosphorylated TAK1 species with functional impact on NF-B and -catenin signaling in human Cutaneous T-cell lymphoma.Leukemia. 2018 Oct;32(10):2211-2223. doi: 10.1038/s41375-018-0066-4. Epub 2018 Feb 22.
130 The Effects of Lentivirus-mediated shRNA Interference Targeting Mcl-1 on Growth of NK/T-cell Lymphoma.Neoplasma. 2017;64(4):511-517. doi: 10.4149/neo_2017_404.
131 Mutational landscape of T-cell lymphoma in mice lacking the DNA mismatch repair gene Mlh1: no synergism with ionizing radiation.Carcinogenesis. 2019 Apr 29;40(2):216-224. doi: 10.1093/carcin/bgz013.
132 Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients.Blood. 2017 Apr 13;129(15):2143-2147. doi: 10.1182/blood-2016-10-747477. Epub 2017 Jan 31.
133 Flow cytometry aneuploidy and cell cycle indexing as a possible tool for differentiating between CD10(+) diffuse large B-cell lymphoma and follicular lymphoma.Cytometry B Clin Cytom. 2020 Sep;98(5):449-453. doi: 10.1002/cyto.b.21861. Epub 2019 Dec 9.
134 Two cases of aquaporin-4 positive neuromyelitis optica associated with T-cell lymphoma.J Neuroimmunol. 2020 Jan 15;338:577092. doi: 10.1016/j.jneuroim.2019.577092. Epub 2019 Oct 30.
135 Non-Hodgkin lymphoma related to hereditary nonpolyposis colorectal cancer in a patient with a novel heterozygous complex deletion in the MSH2 gene.Genes Chromosomes Cancer. 2008 Apr;47(4):326-32. doi: 10.1002/gcc.20536.
136 The anti-invasive role of novel synthesized pyridazine hydrazide appended phenoxy acetic acid against neoplastic development targeting matrix metallo proteases.Biomed Pharmacother. 2017 Nov;95:375-386. doi: 10.1016/j.biopha.2017.08.105. Epub 2017 Sep 12.
137 MYD88 L265P MUTATION DETECTION IN THE AQUEOUS HUMOR OF PATIENTS WITH VITREORETINAL LYMPHOMA.Retina. 2019 Apr;39(4):679-684. doi: 10.1097/IAE.0000000000002319.
138 Hodgkin-Reed-Sternberg cells in classical Hodgkin lymphoma show alterations of genes encoding the NADPH oxidase complex and impaired reactive oxygen species synthesis capacity.PLoS One. 2013 Dec 23;8(12):e84928. doi: 10.1371/journal.pone.0084928. eCollection 2013.
139 Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy.J Immunother Cancer. 2019 May 24;7(1):138. doi: 10.1186/s40425-019-0612-2.
140 Enhanced antitumor effect of cisplatin in human oral squamous cell carcinoma cells by tumor suppressor GRIM?9.Mol Med Rep. 2015 Dec;12(6):8185-92. doi: 10.3892/mmr.2015.4423. Epub 2015 Oct 9.
141 Myc suppression of Nfkb2 accelerates lymphomagenesis.BMC Cancer. 2010 Jul 2;10:348. doi: 10.1186/1471-2407-10-348.
142 NDPKA is not just a metastasis suppressor - be aware of its metastasis-promoting role in neuroblastoma.Lab Invest. 2018 Feb;98(2):219-227. doi: 10.1038/labinvest.2017.105. Epub 2017 Oct 9.
143 SHP-1 promoter 2 methylation in normal epithelial tissues and demethylation in psoriasis.J Mol Med (Berl). 2006 Feb;84(2):175-82. doi: 10.1007/s00109-005-0020-6. Epub 2005 Dec 31.
144 Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in MCL patients independent of CCND1.Leukemia. 2016 Mar;30(3):580-93. doi: 10.1038/leu.2015.140. Epub 2015 May 15.
145 PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's lymphoma and other highly proliferative malignant cells.Blood Cells Mol Dis. 2001 Sep-Oct;27(5):825-9. doi: 10.1006/bcmd.2001.0452.
146 Pim2 cooperates with PML-RARalpha to induce acute myeloid leukemia in a bone marrow transplantation model.Blood. 2010 Jun 3;115(22):4507-16. doi: 10.1182/blood-2009-03-210070. Epub 2010 Mar 9.
147 The telomerase inhibitor PinX1 is a major haploinsufficient tumor suppressor essential for chromosome stability in mice.J Clin Invest. 2011 Apr;121(4):1266-82. doi: 10.1172/JCI43452. Epub 2011 Mar 23.
148 The deregulated promoter methylation of the Polo-like kinases as a potential biomarker in hematological malignancies.Leuk Lymphoma. 2015 Jul;56(7):2123-33. doi: 10.3109/10428194.2014.971407. Epub 2015 Jan 24.
149 Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics.Gene Ther. 2010 Dec;17(12):1506-16. doi: 10.1038/gt.2010.103. Epub 2010 Aug 5.
150 The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.BMC Cancer. 2012 Jun 8;12:229. doi: 10.1186/1471-2407-12-229.
151 Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen.Hematology. 2012 Apr;17 Suppl 1:S90-2. doi: 10.1179/102453312X13336169155970.
152 Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT/-catenin and AKT/GSK3 proliferative signaling.J Biol Chem. 2019 May 10;294(19):7692-7710. doi: 10.1074/jbc.RA119.007640. Epub 2019 Mar 18.
153 Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.J Clin Oncol. 2014 Mar 10;32(8):798-808. doi: 10.1200/JCO.2013.51.5304. Epub 2013 Dec 16.
154 Polymorphisms in integrin genes and lymphoma risk.Leuk Res. 2011 Jul;35(7):968-70. doi: 10.1016/j.leukres.2010.12.012. Epub 2011 Jan 15.
155 Development of new PTK7-targeting aptamer-fluorescent and -radiolabelled probes for evaluation as molecular imaging agents: Lymphoma and melanoma in vivo proof of concept.Bioorg Med Chem. 2017 Feb 1;25(3):1163-1171. doi: 10.1016/j.bmc.2016.12.026. Epub 2016 Dec 24.
156 TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies.Cytokine. 2016 Jun;82:52-7. doi: 10.1016/j.cyto.2015.12.025. Epub 2016 Jan 23.
157 5-Azacitidine induces demethylation of PTPL1 and inhibits growth in non-Hodgkin lymphoma.Int J Mol Med. 2015 Sep;36(3):698-704. doi: 10.3892/ijmm.2015.2269. Epub 2015 Jul 1.
158 Benzoquinone, a leukemogenic metabolite of benzene, catalytically inhibits the protein tyrosine phosphatase PTPN2 and alters STAT1 signaling.J Biol Chem. 2019 Aug 16;294(33):12483-12494. doi: 10.1074/jbc.RA119.008666. Epub 2019 Jun 27.
159 EBV and KSHV Infection Dysregulates Autophagy to Optimize Viral Replication, Prevent Immune Recognition and Promote Tumorigenesis.Viruses. 2018 Oct 31;10(11):599. doi: 10.3390/v10110599.
160 PKK deficiency in B cells prevents lupus development in Sle lupus mice.Immunol Lett. 2017 May;185:1-11. doi: 10.1016/j.imlet.2017.03.002. Epub 2017 Mar 6.
161 Cell cycle and apoptosis regulatory protein (CARP)-1 is a novel, adriamycin-inducible, diffuse large B-cell lymphoma (DLBL) growth suppressor.Cancer Chemother Pharmacol. 2011 Jun;67(6):1401-13. doi: 10.1007/s00280-010-1442-6. Epub 2010 Aug 31.
162 Retinoic Acid Receptor-Related Orphan Receptors: Critical Roles in Tumorigenesis.Front Immunol. 2018 May 31;9:1187. doi: 10.3389/fimmu.2018.01187. eCollection 2018.
163 SUMOylation Confers Posttranslational Stability on NPM-ALK Oncogenic Protein.Neoplasia. 2015 Sep;17(9):742-754. doi: 10.1016/j.neo.2015.09.005.
164 Runx1 Orchestrates Sphingolipid Metabolism and Glucocorticoid Resistance in Lymphomagenesis.J Cell Biochem. 2017 Jun;118(6):1432-1441. doi: 10.1002/jcb.25802. Epub 2017 Jan 10.
165 Collaboration of MYC and RUNX2 in lymphoma simulates T-cell receptor signaling and attenuates p53 pathway activity.J Cell Biochem. 2019 Oct;120(10):18332-18345. doi: 10.1002/jcb.29143. Epub 2019 Jun 30.
166 Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.Mol Cancer Ther. 2014 Jan;13(1):154-64. doi: 10.1158/1535-7163.MCT-13-0466. Epub 2013 Oct 18.
167 STK38 is a critical upstream regulator of MYC's oncogenic activity in human B-cell lymphoma.Oncogene. 2013 Nov 7;32(45):5283-91. doi: 10.1038/onc.2012.543. Epub 2012 Nov 26.
168 EBV Negative Lymphoma and Autoimmune Lymphoproliferative Syndrome Like Phenotype Extend the Clinical Spectrum of Primary Immunodeficiency Caused by STK4 Deficiency.Front Immunol. 2018 Oct 16;9:2400. doi: 10.3389/fimmu.2018.02400. eCollection 2018.
169 SYK regulates mTOR signaling in AML.Leukemia. 2013 Nov;27(11):2118-28. doi: 10.1038/leu.2013.89. Epub 2013 Mar 28.
170 Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing. J Invest Dermatol. 2017 Sep;137(9):1984-1994. doi: 10.1016/j.jid.2017.04.010. Epub 2017 May 4.
171 The NF-B subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphoma.Oncogene. 2016 Jun 30;35(26):3476-84. doi: 10.1038/onc.2015.399. Epub 2015 Nov 2.
172 Gene dosage reductions of Trf1 and/or Tin2 induce telomere DNA damage and lymphoma formation in aging mice.Leukemia. 2017 Dec;31(12):2853. doi: 10.1038/leu.2017.224. Epub 2017 Nov 10.
173 Up-regulation of T-lymphoma and metastasis gene 1 in gastric cancer and its involvement in cell invasion and migration.Chin Med J (Engl). 2013 Feb;126(4):640-5.
174 TIRAP p.R81C is a novel lymphoma risk variant which enhances cell proliferation via NF-B mediated signaling in B-cells.Haematologica. 2019 Apr;104(4):766-777. doi: 10.3324/haematol.2018.201590. Epub 2018 Oct 31.
175 A sensitive and kinetically defined radiochemical assay for canine and human serum thymidine kinase 1 (TK1) to monitor canine malignant lymphoma.Vet J. 2012 Oct;194(1):40-7. doi: 10.1016/j.tvjl.2012.03.006. Epub 2012 Apr 18.
176 CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell.J Immunol. 2003 Mar 1;170(5):2582-9. doi: 10.4049/jimmunol.170.5.2582.
177 Breast Cancer (18)F-ISO-1 Uptake as a Marker of Proliferation Status.J Nucl Med. 2020 May;61(5):665-670. doi: 10.2967/jnumed.119.232363. Epub 2019 Dec 13.
178 Development of a high-resolution melting method for the screening of TNFAIP3 gene mutations.Oncol Rep. 2016 May;35(5):2936-42. doi: 10.3892/or.2016.4662. Epub 2016 Mar 8.
179 Genetic variants in interleukin-2 and risk of lymphoma among children in Korea.Asian Pac J Cancer Prev. 2012;13(2):621-3. doi: 10.7314/apjcp.2012.13.2.621.
180 CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.Sci Transl Med. 2019 Sep 25;11(511):eaaw9414. doi: 10.1126/scitranslmed.aaw9414.
181 Enhancing immunotherapy of STING agonist for lymphoma in preclinical models.Blood Adv. 2018 Sep 11;2(17):2230-2241. doi: 10.1182/bloodadvances.2018020040.
182 Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking.Sci Rep. 2018 Feb 2;8(1):2278. doi: 10.1038/s41598-018-20656-y.
183 CD137 deficiency causes immune dysregulation with predisposition to lymphomagenesis.Blood. 2019 Oct 31;134(18):1510-1516. doi: 10.1182/blood.2019000644.
184 Genetic contributors and soluble mediators in prediction of autoimmune comorbidity.J Autoimmun. 2019 Nov;104:102317. doi: 10.1016/j.jaut.2019.102317. Epub 2019 Aug 20.
185 Adenovirus-mediated LIGHT gene modification in murine B-cell lymphoma elicits a potent antitumor effect.Cell Mol Immunol. 2010 Jul;7(4):296-305. doi: 10.1038/cmi.2010.15. Epub 2010 Apr 26.
186 Combined cellular and soluble mediator analysis for improved diagnosis of vitreoretinal lymphoma.Acta Ophthalmol. 2019 Sep;97(6):626-632. doi: 10.1111/aos.14036. Epub 2019 Jan 27.
187 Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma.Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16541-16550. doi: 10.1073/pnas.1903991116. Epub 2019 Jul 25.
188 Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma.Nat Med. 2019 Jan;25(1):130-140. doi: 10.1038/s41591-018-0262-9. Epub 2018 Dec 3.
189 Rapid xenograft tumor progression in beta-arrestin1 transgenic mice due to enhanced tumor angiogenesis.FASEB J. 2008 Feb;22(2):355-64. doi: 10.1096/fj.07-9046com. Epub 2007 Sep 21.
190 Promoter methylation of the bone morphogenetic protein-6 gene in association with adult T-cell leukemia.Int J Cancer. 2008 Oct 15;123(8):1824-31. doi: 10.1002/ijc.23749.
191 Pharmacological inhibition of carbonic anhydrase XII interferes with cell proliferation and induces cell apoptosis in T-cell lymphomas.Cancer Lett. 2013 Jun 1;333(1):76-88. doi: 10.1016/j.canlet.2013.01.020. Epub 2013 Jan 21.
192 Jun activation domain-binding protein 1 negatively regulate p27 kip1 in non-Hodgkin's lymphomas.Cancer Biol Ther. 2008 Mar;7(3):460-7. doi: 10.4161/cbt.7.3.5456. Epub 2007 Dec 21.
193 Clinical significance of co-expression of CD21 and LFA-1 in B-cell lymphoma.Int J Hematol. 2009 May;89(4):497-507. doi: 10.1007/s12185-009-0303-8. Epub 2009 Apr 11.
194 Regulation of dipeptidyl peptidase 8 and 9 expression in activated lymphocytes and injured liver.World J Gastroenterol. 2013 May 21;19(19):2883-93. doi: 10.3748/wjg.v19.i19.2883.
195 Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies.Blood. 2007 Oct 15;110(8):2931-9. doi: 10.1182/blood-2006-11-058750. Epub 2007 Jul 12.
196 Human T-leukemia and T-lymphoma express glutamate receptor AMPA GluR3, and the neurotransmitter glutamate elevates the cancer-related matrix-metalloproteinases inducer CD147/EMMPRIN, MMP-9 secretion and engraftment of T-leukemia in vivo.Leuk Lymphoma. 2009 Jun;50(6):985-97. doi: 10.1080/10428190902878448.
197 CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.Haematologica. 2019 Apr;104(4):749-755. doi: 10.3324/haematol.2018.205252. Epub 2018 Oct 25.
198 A novel monoclonal antibody, KOR-SA3544 which reacts to Philadelphia chromosome-positive acute lymphoblastic leukemia cells with high sensitivity.Leukemia. 1995 Jul;9(7):1233-9.
199 PDCD2, a protein whose expression is repressed by BCL6, induces apoptosis in human cells by activation of the caspase cascade.Blood Cells Mol Dis. 2010 Aug 15;45(2):169-75. doi: 10.1016/j.bcmd.2010.04.007. Epub 2010 Jun 3.
200 A novel TRB@/NOTCH1 fusion gene in T-cell lymphoblastic lymphoma with t(7;9)(q34;q34).Eur J Haematol. 2013 Jan;90(1):68-75. doi: 10.1111/ejh.12019. Epub 2012 Nov 29.
201 CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity.Cancer Res. 2017 Sep 15;77(18):5118-5128. doi: 10.1158/0008-5472.CAN-16-0342. Epub 2017 Jul 17.
202 Cell cycle arrest induced by engagement of B7-H4 on Epstein-Barr virus-positive B-cell lymphoma cell lines.Immunology. 2009 Nov;128(3):360-8. doi: 10.1111/j.1365-2567.2009.03111.x.
203 Expression of ABCB5 gene in hematological malignances and its significance.Leuk Lymphoma. 2012 Jun;53(6):1211-5. doi: 10.3109/10428194.2011.637214. Epub 2011 Dec 7.
204 UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan.Ann Hematol. 2015 Jan;94(1):65-9. doi: 10.1007/s00277-014-2170-5. Epub 2014 Jul 25.
205 Prognostic Value of Accumulative Expression of COX-2 and p53 in Small and Diffuse Large B Cell Lymphoma.Pathol Oncol Res. 2020 Apr;26(2):1183-1190. doi: 10.1007/s12253-019-00674-5. Epub 2019 Jun 11.
206 Uridine kinase: altered subunit size or enzyme expression as a function of cell type, growth stimulation, or mutagenesis.J Cell Biochem. 1987 Nov;35(3):217-29. doi: 10.1002/jcb.240350305.
207 Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial.Br J Haematol. 2018 Nov;183(4):601-607. doi: 10.1111/bjh.15585. Epub 2018 Sep 14.
208 N-acetyltransferase polymorphisms are associated with risk of lymphoma subtypes.Hematol Oncol. 2016 Jun;34(2):79-83. doi: 10.1002/hon.2193. Epub 2015 Feb 17.
209 Increased expression of the spindle checkpoint protein BubR1 is associated with high cell proliferation in primary gastrointestinal diffuse large B cell lymphoma.Cell Biochem Biophys. 2013 Jul;66(3):747-52. doi: 10.1007/s12013-013-9519-6.
210 The early variation of left ventricular twisting function in patients with lymphoma received anthracycline therapy assessed by three-dimensional speckle tracking echocardiography.Cardiol J. 2017;24(5):484-494. doi: 10.5603/CJ.a2017.0035. Epub 2017 Mar 29.
211 Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma.Exp Hematol. 2015 Jul;43(7):534-6. doi: 10.1016/j.exphem.2015.04.006. Epub 2015 Apr 27.
212 A rare case of asynchronous bilateral B-cell lymphoma of the breast.Jpn J Clin Oncol. 1989 Dec;19(4):391-6.
213 The lymphocyte metalloprotease MDC-L (ADAM 28) is a ligand for the integrin alpha4beta1.J Biol Chem. 2002 Feb 1;277(5):3784-92. doi: 10.1074/jbc.M109538200. Epub 2001 Nov 27.
214 Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization.Blood. 1989 Aug 1;74(2):810-6.
215 Single and combined BTK and PI3K inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.Br J Haematol. 2019 Dec;187(5):595-601. doi: 10.1111/bjh.16118. Epub 2019 Jul 29.
216 Five-year study assessing the clinical utility of anti-Mllerian hormone measurements in reproductive-age women with cancer.Reprod Biomed Online. 2019 Oct;39(4):712-720. doi: 10.1016/j.rbmo.2019.06.001. Epub 2019 Jun 11.
217 Plasma membrane sequestration of apoptotic protease-activating factor-1 in human B-lymphoma cells: a novel mechanism of chemoresistance.Blood. 2005 May 15;105(10):4070-7. doi: 10.1182/blood-2004-10-4075. Epub 2005 Feb 3.
218 Enhanced tumor formation in mice heterozygous for Blm mutation.Science. 2002 Sep 20;297(5589):2051-3. doi: 10.1126/science.1074340.
219 Concise Review: Cheating Death for a Better Transplant.Stem Cells. 2018 Nov;36(11):1646-1654. doi: 10.1002/stem.2901. Epub 2018 Oct 1.
220 CART cell therapy for prostate cancer: status and promise.Onco Targets Ther. 2019 Jan 3;12:391-395. doi: 10.2147/OTT.S185556. eCollection 2019.
221 Overexpression of CCDC34 in colorectal cancer and its involvement in tumor growth, apoptosis and invasion.Mol Med Rep. 2018 Jan;17(1):465-473. doi: 10.3892/mmr.2017.7860. Epub 2017 Oct 24.
222 Id2 Collaborates with Id3 To Suppress Invariant NKT and Innate-like Tumors.J Immunol. 2017 Apr 15;198(8):3136-3148. doi: 10.4049/jimmunol.1601935. Epub 2017 Mar 3.
223 Anaplastic variant of diffuse large B-cell lymphoma with hallmark cell appearance: Two cases highlighting a broad diversity in the diagnostics.Pathol Int. 2018 Apr;68(4):251-255. doi: 10.1111/pin.12653. Epub 2018 Feb 25.
224 p53 expression in large B-cell lymphomas with MYC extra copies and CD99 expression in large B-cell lymphomas in relation to MYC status.Hum Pathol. 2019 Apr;86:21-31. doi: 10.1016/j.humpath.2018.11.015. Epub 2018 Nov 26.
225 Structural abnormalities of the X chromosome in non-Hodgkin's lymphoma.Leukemia. 1993 Jun;7(6):848-52.
226 ALK-positive diffuse large B-cell lymphoma of the stomach associated with a clathrin-ALK rearrangement.Hum Pathol. 2004 Oct;35(10):1285-8. doi: 10.1016/j.humpath.2004.06.001.
227 Reduced oncogenicity of p190 Bcr/Abl F-actin-binding domain mutants.Blood. 2000 Sep 15;96(6):2226-32.
228 Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry.Blood. 1994 Dec 1;84(11):3648-52.
229 Proposed rituximab biosimilar BCD-020 versus reference rituximab for treatment of patients with indolent non-Hodgkin lymphomas: An international multicenter randomized trial.Hematol Oncol. 2020 Feb;38(1):67-73. doi: 10.1002/hon.2693. Epub 2020 Jan 13.
230 VASA is a specific marker for both normal and malignant human germ cells.Lab Invest. 2002 Feb;82(2):159-66. doi: 10.1038/labinvest.3780408.
231 Interphase detection of BCL6/IgH fusion gene in non-Hodgkin lymphoma by fluorescence in situ hybridization.Cancer Genet Cytogenet. 1997 Dec;99(2):102-7. doi: 10.1016/s0165-4608(97)00203-3.
232 Expression of DHX32 in lymphoid tissues.Exp Mol Pathol. 2005 Dec;79(3):219-23. doi: 10.1016/j.yexmp.2005.07.002. Epub 2005 Sep 21.
233 BET Inhibition-Induced GSK3 Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors.Cell Rep. 2018 Aug 21;24(8):2155-2166. doi: 10.1016/j.celrep.2018.07.055.
234 Isolation and characterization of bovine and mouse terminal deoxynucleotidyltransferase cDNAs expressible in mammalian cells.Nucleic Acids Res. 1986 Jul 25;14(14):5777-92. doi: 10.1093/nar/14.14.5777.
235 Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts.J Clin Endocrinol Metab. 2018 Sep 1;103(9):3169-3182. doi: 10.1210/jc.2017-01845.
236 Round cell tumours of bone.Pathol Res Pract. 1993 Dec;189(10):111-36.
237 NSE from diffuse large B-cell lymphoma cells regulates macrophage polarization.Cancer Manag Res. 2019 May 17;11:4577-4595. doi: 10.2147/CMAR.S203010. eCollection 2019.
238 Berberine reinforces Sertoli cells niche and accelerates spermatogonial stem cells renewal in experimentally-induced varicocele condition in rats.Phytomedicine. 2018 Feb 1;40:68-78. doi: 10.1016/j.phymed.2017.12.036. Epub 2018 Jan 2.
239 The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis.Mol Cell Biol. 2005 Mar;25(6):2395-405. doi: 10.1128/MCB.25.6.2395-2405.2005.
240 Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies.Clin Cancer Res. 2005 Jan 1;11(1):87-96.
241 Expression of interleukin-9 in nasal natural killer/T-cell lymphoma cell lines and patients.Clin Cancer Res. 2005 Dec 1;11(23):8250-7. doi: 10.1158/1078-0432.CCR-05-1426.
242 The human placental growth hormone variant is mitogenic for rat lymphoma Nb2 cells.Endocrinology. 1990 Feb;126(2):971-6. doi: 10.1210/endo-126-2-971.
243 Agranular CD4+CD56+ blastic natural killer leukemia/lymphoma.Ann Hematol. 2001 Apr;80(4):228-31. doi: 10.1007/s002770000257.
244 Haptoglobin-related protein as a serum marker in malignant lymphoma.Pathol Oncol Res. 1998;4(4):271-6. doi: 10.1007/BF02905217.
245 The adaptor protein HSH2 attenuates apoptosis in response to ligation of the B cell antigen receptor complex on the B lymphoma cell line, WEHI-231.J Biol Chem. 2005 Feb 4;280(5):3507-15. doi: 10.1074/jbc.M407690200. Epub 2004 Nov 29.
246 Expression of HYAL2 mRNA, hyaluronan and hyaluronidase in B-cell non-Hodgkin lymphoma: relationship with tumor aggressiveness.Int J Cancer. 2005 Jan 10;113(2):207-12. doi: 10.1002/ijc.20562.
247 A variant Burkitt-type translocation (2p-;8q+) in a patient with diffuse large cell lymphoma.Cancer Genet Cytogenet. 1987 Feb;24(2):225-9. doi: 10.1016/0165-4608(87)90103-8.
248 T(11;18)-bearing pulmonary mucosa-associated lymphoid tissue lymphoma responding to cladribine.Int J Hematol. 2004 Jul;80(1):70-4. doi: 10.1532/ijh97.03170.
249 Primary gastric T-cell lymphoma with and without human T-lymphotropic virus type 1.Cancer. 1997 Jul 15;80(2):292-303. doi: 10.1002/(sici)1097-0142(19970715)80:2<292::aid-cncr18>3.0.co;2-p.
250 Epstein-Barr virus-negative extranodal "true" natural killer-cell lymphoma harbouring a KDM6A mutation.Hematol Oncol. 2018 Feb;36(1):328-335. doi: 10.1002/hon.2459. Epub 2017 Jul 10.
251 Expression of the MDR1 and MRP genes in patients with lymphoma with primary bone marrow involvement.Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(6-7):843-7. doi: 10.1081/NCN-200026029.
252 Systemic therapy in non-conventional cancers of the larynx.Oral Oncol. 2018 Jul;82:61-68. doi: 10.1016/j.oraloncology.2018.05.005. Epub 2018 May 26.
253 Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.Eur J Immunol. 1995 May;25(5):1374-84. doi: 10.1002/eji.1830250536.
254 A novel diffuse large B-cell lymphoma-associated cancer testis antigen encoding a PAS domain protein.Br J Cancer. 2004 Jul 5;91(1):141-9. doi: 10.1038/sj.bjc.6601875.
255 Deletion of the Miz-1 POZ Domain Increases Efficacy of Cytarabine Treatment in T- and B-ALL/Lymphoma Mouse Models.Cancer Res. 2019 Aug 15;79(16):4184-4195. doi: 10.1158/0008-5472.CAN-18-3038. Epub 2019 Jul 4.
256 TAPP1 and TAPP2 are targets of phosphatidylinositol 3-kinase signaling in B cells: sustained plasma membrane recruitment triggered by the B-cell antigen receptor.Mol Cell Biol. 2002 Aug;22(15):5479-91. doi: 10.1128/MCB.22.15.5479-5491.2002.
257 Germline variation in the 3'-untranslated region of the POU2AF1 gene is associated with susceptibility to lymphoma.Mol Carcinog. 2017 Aug;56(8):1945-1952. doi: 10.1002/mc.22652. Epub 2017 Apr 19.
258 Alterations of the PPP1R3 gene in hematological malignancies.Int J Oncol. 2000 Oct;17(4):717-21. doi: 10.3892/ijo.17.4.717.
259 New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.Anticancer Res. 2004 Mar-Apr;24(2B):865-71.
260 Mutations of a novel human RAD54 homologue, RAD54B, in primary cancer.Oncogene. 1999 Jun 3;18(22):3422-6. doi: 10.1038/sj.onc.1202691.
261 RAG1/2 induces genomic insertions by mobilizing DNA into RAG1/2-independent breaks.J Exp Med. 2017 Mar 6;214(3):815-831. doi: 10.1084/jem.20161638. Epub 2017 Feb 8.
262 Genetic alterations disrupting the nuclear localization of the retinoblastoma-related gene RB2/p130 in human tumor cell lines and primary tumors.Cancer Res. 2000 Jan 15;60(2):383-9.
263 Hypermethylation-associated Inactivation of the Cellular Retinol-Binding-Protein 1 Gene in Human Cancer.Cancer Res. 2002 Oct 15;62(20):5902-5.
264 The regulator of calcineurin 1 (RCAN1) inhibits nuclear factor kappaB signaling pathway and suppresses human malignant glioma cells growth.Oncotarget. 2017 Feb 14;8(7):12003-12012. doi: 10.18632/oncotarget.14479.
265 Immunophenotypic Shifts in Primary Cutaneous T-Cell Lymphoma Suggest Antigenic Modulation: A Study of Sequential Biopsy Specimens.Am J Surg Pathol. 2017 Apr;41(4):431-445. doi: 10.1097/PAS.0000000000000786.
266 Homozygous deletions and point mutations of the Rit1/Bcl11b gene in gamma-ray induced mouse thymic lymphomas.Biochem Biophys Res Commun. 2003 Feb 7;301(2):598-603. doi: 10.1016/s0006-291x(02)03069-3.
267 Notch signal transduction is not regulated by SEL1L in leukaemia and lymphoma cells in culture.Anticancer Res. 2002 Nov-Dec;22(6C):4211-4.
268 The effects of a growth-inhibiting tripeptide, acetylGlu-Ser-GlyNH2 (Ac-ESG), on gene expression and cell cycle progression of two lymphoma cell lines.Anticancer Res. 2003 Jul-Aug;23(4):3159-65.
269 In vitro canine distemper virus infection of canine lymphoid cells: a prelude to oncolytic therapy for lymphoma.Clin Cancer Res. 2005 Feb 15;11(4):1579-87. doi: 10.1158/1078-0432.CCR-04-1944.
270 Ig VH gene expression among human follicular lymphomas.Blood. 1991 Sep 15;78(6):1561-8.
271 Purification, cDNA cloning, and expression of human sorcin in vincristine-resistant HOB1 lymphoma cell lines.Arch Biochem Biophys. 1996 Jan 15;325(2):217-26. doi: 10.1006/abbi.1996.0027.
272 Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma: correlation with clinical outcome.Leuk Lymphoma. 2002 Dec;43(12):2309-17. doi: 10.1080/1042819021000040017.
273 Effusion and solid lymphomas have distinctive gene and protein expression profiles in an animal model of primary effusion lymphoma.J Pathol. 2006 Aug;209(4):464-73. doi: 10.1002/path.2012.
274 Epm2a suppresses tumor growth in an immunocompromised host by inhibiting Wnt signaling.Cancer Cell. 2006 Sep;10(3):179-90. doi: 10.1016/j.ccr.2006.08.008.
275 Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis.Blood. 2005 Sep 1;106(5):1831-8. doi: 10.1182/blood-2004-10-3898. Epub 2005 May 24.
276 AHI-1: a novel signaling protein and potential therapeutic target in human leukemia and brain disorders.Oncotarget. 2011 Dec;2(12):918-34. doi: 10.18632/oncotarget.405.
277 Inhibition of BCL11B expression leads to apoptosis of malignant but not normal mature T cells.Oncogene. 2007 May 31;26(26):3797-810. doi: 10.1038/sj.onc.1210152. Epub 2006 Dec 18.
278 Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma.Haematologica. 2017 Oct;102(10):1758-1766. doi: 10.3324/haematol.2016.160192. Epub 2017 Jul 27.
279 Protective effect of human serum amyloid P on CCl4-induced acute liver injury in mice.Int J Mol Med. 2017 Aug;40(2):454-464. doi: 10.3892/ijmm.2017.3028. Epub 2017 Jun 14.
280 Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors.Cancer Immunol Res. 2015 Jul;3(7):815-26. doi: 10.1158/2326-6066.CIR-15-0054. Epub 2015 May 4.
281 Primary malignant lymphoma of the brain: frequent abnormalities and inactivation of p14 tumor suppressor gene.Cancer Sci. 2005 Jan;96(1):38-41. doi: 10.1111/j.1349-7006.2005.00003.x.
282 EBV latent membrane protein 2A orchestrates p27(kip1) degradation via Cks1 to accelerate MYC-driven lymphoma in mice.Blood. 2017 Dec 7;130(23):2516-2526. doi: 10.1182/blood-2017-07-796821. Epub 2017 Oct 26.
283 Human endogenous retrovirus K (HML-2) elements in the plasma of people with lymphoma and breast cancer.J Virol. 2008 Oct;82(19):9329-36. doi: 10.1128/JVI.00646-08. Epub 2008 Jul 16.
284 Identifying gene disruptions in novel balanced de novo constitutional translocations in childhood cancer patients by whole-genome sequencing.Genet Med. 2015 Oct;17(10):831-5. doi: 10.1038/gim.2014.189. Epub 2015 Jan 8.
285 DLC-1 as a modulator of proliferation, apoptosis and migration in Burkitt's lymphoma cells.Mol Biol Rep. 2011 Mar;38(3):1915-20. doi: 10.1007/s11033-010-0311-z. Epub 2010 Oct 1.
286 Epigenetic silencing of the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomas.J Transl Med. 2012 Oct 11;10:209. doi: 10.1186/1479-5876-10-209.
287 The Transcription Factor ASCIZ and Its Target DYNLL1 Are Essential for the Development and Expansion of MYC-Driven B Cell Lymphoma.Cell Rep. 2016 Feb 16;14(6):1488-1499. doi: 10.1016/j.celrep.2016.01.012. Epub 2016 Jan 28.
288 DNA repair gene polymorphisms in B cell non-Hodgkin's lymphoma.Tumour Biol. 2015 Mar;36(3):2155-61. doi: 10.1007/s13277-014-2825-9. Epub 2014 Nov 18.
289 Expression of syncytin in leukemia and lymphoma cells.Leuk Res. 2010 Sep;34(9):1195-202. doi: 10.1016/j.leukres.2010.03.016. Epub 2010 Apr 2.
290 Suppression of Myc oncogenic activity by nucleostemin haploinsufficiency.Oncogene. 2012 Jul 12;31(28):3311-21. doi: 10.1038/onc.2011.507. Epub 2011 Nov 14.
291 Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk.Genes Immun. 2006 Dec;7(8):615-24. doi: 10.1038/sj.gene.6364337. Epub 2006 Sep 14.
292 Mapping of transcription factor motifs in active chromatin identifies IRF5 as key regulator in classical Hodgkin lymphoma.Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):E4513-22. doi: 10.1073/pnas.1406985111. Epub 2014 Oct 6.
293 PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.Nat Med. 2012 Nov;18(11):1699-704. doi: 10.1038/nm.2966. Epub 2012 Oct 14.
294 Killer cell immunoglobulin-like receptor 2DL4 is expressed in and suppresses the cell growth of Langerhans cell histiocytosis.Oncotarget. 2017 Jun 6;8(23):36964-36972. doi: 10.18632/oncotarget.16936.
295 Galectin-1-mediated cell adhesion, invasion and cell death in human anaplastic large cell lymphoma: regulatory roles of cell surface glycans.Int J Oncol. 2014 May;44(5):1433-42. doi: 10.3892/ijo.2014.2319. Epub 2014 Mar 4.
296 Increased galectin-7 gene expression in lymphoma cells is under the control of DNA methylation.Biochem Biophys Res Commun. 2009 Sep 25;387(3):425-9. doi: 10.1016/j.bbrc.2009.07.015. Epub 2009 Jul 9.
297 Latexin is down-regulated in hematopoietic malignancies and restoration of expression inhibits lymphoma growth.PLoS One. 2012;7(9):e44979. doi: 10.1371/journal.pone.0044979. Epub 2012 Sep 27.
298 The role of centrosomal Nlp in the control of mitotic progression and tumourigenesis.Br J Cancer. 2011 May 10;104(10):1523-8. doi: 10.1038/bjc.2011.130. Epub 2011 Apr 19.
299 Spectrum of Atypical Clinical Presentations in Patients with Biallelic PRF1 Missense Mutations.Pediatr Blood Cancer. 2015 Dec;62(12):2094-100. doi: 10.1002/pbc.25646. Epub 2015 Jul 16.
300 Acquired STAT4 deficiency as a consequence of cancer chemotherapy.Blood. 2011 Dec 1;118(23):6097-106. doi: 10.1182/blood-2011-03-341867. Epub 2011 Oct 13.
301 Epigenetic inactivation of the Groucho homologue gene TLE1 in hematologic malignancies.Cancer Res. 2008 Jun 1;68(11):4116-22. doi: 10.1158/0008-5472.CAN-08-0085.
302 Transient responses to NOTCH and TLX1/HOX11 inhibition in T-cell acute lymphoblastic leukemia/lymphoma.PLoS One. 2011 Feb 4;6(2):e16761. doi: 10.1371/journal.pone.0016761.
303 Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome.Int J Oncol. 2008 Sep;33(3):549-54.
304 Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas.Leukemia. 2011 Dec;25(12):1882-90. doi: 10.1038/leu.2011.168. Epub 2011 Jul 22.
305 Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.MAbs. 2014 Jul-Aug;6(4):1026-37. doi: 10.4161/mabs.28699.
306 ACOX1 destabilizes p73 to suppress intrinsic apoptosis pathway and regulates sensitivity to doxorubicin in lymphoma cells.BMB Rep. 2019 Sep;52(9):566-571. doi: 10.5483/BMBRep.2019.52.9.094.
307 The CBFA2T3/ACSF3 locus is recurrently involved in IGH chromosomal translocation t(14;16)(q32;q24) in pediatric B-cell lymphoma with germinal center phenotype.Genes Chromosomes Cancer. 2012 Apr;51(4):338-43. doi: 10.1002/gcc.21919.
308 TFG, a target of chromosome translocations in lymphoma and soft tissue tumors, fuses to GPR128 in healthy individuals.Haematologica. 2010 Jan;95(1):20-6. doi: 10.3324/haematol.2009.011536. Epub 2009 Oct 1.
309 The clastogenicity of 4NQO is cell-type dependent and linked to cytotoxicity, length of exposure and p53 proficiency.Mutagenesis. 2016 Mar;31(2):171-80. doi: 10.1093/mutage/gev069. Epub 2015 Sep 11.
310 TP73, an under-appreciated player in non-Hodgkin lymphoma pathogenesis and management.Curr Mol Med. 2014 May;14(4):432-9. doi: 10.2174/1566524014666140414204458.
311 Crucial Role of Increased Arid3a at the Pre-B and Immature B Cell Stages for B1a Cell Generation.Front Immunol. 2019 Mar 15;10:457. doi: 10.3389/fimmu.2019.00457. eCollection 2019.
312 HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies.Blood. 2014 Aug 21;124(8):1266-76. doi: 10.1182/blood-2014-03-563742. Epub 2014 Jun 26.
313 Sensitisation of c-MYC-induced B-lymphoma cells to apoptosis by ATF2.Oncogene. 2014 Feb 20;33(8):1027-36. doi: 10.1038/onc.2013.28. Epub 2013 Feb 18.
314 Case for diagnosis. Infective dermatitis associated with HTLV-1: differential diagnosis of atopic dermatitis.An Bras Dermatol. 2017 Jul-Aug;92(4):573-574. doi: 10.1590/abd1806-4841.20176684.
315 BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).Ann Hematol. 2019 Aug;98(8):1973-1980. doi: 10.1007/s00277-019-03704-z. Epub 2019 May 20.
316 Body size and obesity during adulthood, and risk of lympho-haematopoietic cancers: an update of the WCRF-AICR systematic review of published prospective studies.Ann Oncol. 2019 Apr 1;30(4):528-541. doi: 10.1093/annonc/mdz045.
317 Intramolecular Interactions and Regulation of Cofactor Binding by the Four Repressive Elements in the Caspase Recruitment Domain-containing Protein 11 (CARD11) Inhibitory Domain.J Biol Chem. 2016 Apr 15;291(16):8338-48. doi: 10.1074/jbc.M116.717322. Epub 2016 Feb 16.
318 Targeting a mitochondrial potassium channel to fight cancer.Cell Calcium. 2015 Jul;58(1):131-8. doi: 10.1016/j.ceca.2014.09.006. Epub 2014 Oct 18.
319 Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention.Cancer Cell. 2019 Sep 16;36(3):250-267.e9. doi: 10.1016/j.ccell.2019.08.001.
320 CD2-Associated Protein Contributes to Hepatitis C, Virus Propagation and Steatosis by Disrupting Insulin Signaling.Hepatology. 2018 Nov;68(5):1710-1725. doi: 10.1002/hep.30073.
321 Signalling pathways identified in salivary glands from primary Sjgren's syndrome patients reveal enhanced adipose tissue development.Autoimmunity. 2018 May;51(3):135-146. doi: 10.1080/08916934.2018.1446525. Epub 2018 Mar 5.
322 Common variants on 14q32 and 13q12 are associated with DLBCL susceptibility.J Hum Genet. 2011 Jun;56(6):436-9. doi: 10.1038/jhg.2011.35. Epub 2011 Apr 7.
323 CDCA7 finely tunes cytoskeleton dynamics to promote lymphoma migration and invasion.Haematologica. 2020 Mar;105(3):730-740. doi: 10.3324/haematol.2018.215459. Epub 2019 Jun 20.
324 The Transitional Endoplasmic Reticulum ATPase p97 Regulates the Alternative Nuclear Factor NF-B Signaling via Partial Degradation of the NF-B Subunit p100.J Biol Chem. 2015 Aug 7;290(32):19558-68. doi: 10.1074/jbc.M114.630061. Epub 2015 Jun 25.
325 Congenital heart disease complexity and childhood cancer risk.Birth Defects Res. 2018 Oct 16;110(17):1314-1321. doi: 10.1002/bdr2.1390. Epub 2018 Oct 16.
326 Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells.Oncotarget. 2018 Apr 20;9(30):21166-21181. doi: 10.18632/oncotarget.24989. eCollection 2018 Apr 20.
327 A novel protein CMTM1-v5 specifically induced human lymphoma cells apoptosis in vitro and in vivo.Exp Cell Res. 2019 Dec 1;385(1):111623. doi: 10.1016/j.yexcr.2019.111623. Epub 2019 Sep 19.
328 The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people.HIV Med. 2018 Feb;19(2):90-101. doi: 10.1111/hiv.12546. Epub 2017 Aug 31.
329 Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.Clin Cancer Res. 2012 Aug 1;18(15):4183-90. doi: 10.1158/1078-0432.CCR-12-1064. Epub 2012 Jun 6.
330 Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.Blood. 2007 Oct 1;110(7):2569-77. doi: 10.1182/blood-2006-12-062927. Epub 2007 Apr 17.
331 Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study.Cancer Manag Res. 2019 Feb 11;11:1363-1372. doi: 10.2147/CMAR.S192143. eCollection 2019.
332 Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.Int J Oncol. 2018 Sep;53(3):1193-1203. doi: 10.3892/ijo.2018.4456. Epub 2018 Jun 27.
333 DIXDC1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) via enhancing p-Akt in Non-Hodgkin's lymphomas.Leuk Res. 2016 Nov;50:104-111. doi: 10.1016/j.leukres.2016.09.011. Epub 2016 Sep 8.
334 Dlx5 Homeodomain:DNA Complex: Structure, Binding and Effect of Mutations Related to Split Hand and Foot Malformation Syndrome.J Mol Biol. 2016 Mar 27;428(6):1130-1141. doi: 10.1016/j.jmb.2016.01.023. Epub 2016 Jan 29.
335 Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target.Blood. 2011 Oct 20;118(16):4421-30. doi: 10.1182/blood-2011-06-364570. Epub 2011 Aug 22.
336 Integrated analysis of 10 lymphoma datasets identifies E2F8 as a key regulator in Burkitt's lymphoma and mantle cell lymphoma.Am J Transl Res. 2019 Jul 15;11(7):4382-4396. eCollection 2019.
337 Overexpression of the immediate-early genes Egr1, Egr2, and Egr3 in two strains of rodents susceptible to audiogenic seizures.Epilepsy Behav. 2017 Jun;71(Pt B):226-237. doi: 10.1016/j.yebeh.2015.12.020. Epub 2016 Jan 14.
338 Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase.Blood. 2014 Dec 11;124(25):3758-67. doi: 10.1182/blood-2014-07-589689. Epub 2014 Oct 15.
339 Expression and activity of eIF6 trigger malignant pleural mesothelioma growth in vivo.Oncotarget. 2015 Nov 10;6(35):37471-85. doi: 10.18632/oncotarget.5462.
340 The oncogenic role of the ETS transcription factors MEF and ERG.Cell Cycle. 2010 Sep 1;9(17):3457-9. doi: 10.4161/cc.9.17.13000. Epub 2010 Sep 13.
341 Rothmund-Thomson syndrome and osteoma cutis in a patient previously diagnosed as COPS syndrome.Eur J Pediatr. 2017 Feb;176(2):279-283. doi: 10.1007/s00431-016-2834-3. Epub 2016 Dec 30.
342 Lymphomagenic properties of a HIV p17 variant derived from a splenic marginal zone lymphoma occurred in a HIV-infected patient.Hematol Oncol. 2019 Apr;37(2):176-184. doi: 10.1002/hon.2562. Epub 2018 Nov 6.
343 Pipeline for large-scale microdroplet bisulfite PCR-based sequencing allows the tracking of hepitype evolution in tumors.PLoS One. 2011;6(7):e21332. doi: 10.1371/journal.pone.0021332. Epub 2011 Jul 5.
344 Angioimmunoblastic T-cell lymphoma and hypereosinophilic syndrome with FIP1L1/PDGFRA fusion gene effectively treated with imatinib: A case report.Medicine (Baltimore). 2017 Sep;96(36):e8001. doi: 10.1097/MD.0000000000008001.
345 The role of fibromodulin in cancer pathogenesis: implications for diagnosis and therapy.Cancer Cell Int. 2019 Jun 10;19:157. doi: 10.1186/s12935-019-0870-6. eCollection 2019.
346 FOXO4 expression is related to stem cell-like properties and resistance to treatment in diffuse large B-cell lymphoma.Oncotarget. 2017 Jan 10;8(2):2466-2476. doi: 10.18632/oncotarget.13690.
347 MicroRNA-376a regulates cell proliferation and apoptosis by targeting forkhead box protein P2 in lymphoma.Oncol Lett. 2018 Sep;16(3):3169-3176. doi: 10.3892/ol.2018.9012. Epub 2018 Jun 22.
348 miR-155 regulates HGAL expression and increases lymphoma cell motility.Blood. 2012 Jan 12;119(2):513-20. doi: 10.1182/blood-2011-08-370536. Epub 2011 Nov 16.
349 From cytopenia to leukemia: the role of Gfi1 and Gfi1b in blood formation.Blood. 2015 Dec 10;126(24):2561-9. doi: 10.1182/blood-2015-06-655043. Epub 2015 Oct 7.
350 Is True Whole-Body (18)F-FDG PET/CT Required in Pediatric Lymphoma? An IAEA Multicenter Prospective Study.J Nucl Med. 2019 Aug;60(8):1087-1093. doi: 10.2967/jnumed.118.222299. Epub 2019 Jan 25.
351 Loss of signalling via G13 in germinal centre B-cell-derived lymphoma.Nature. 2014 Dec 11;516(7530):254-8. doi: 10.1038/nature13765. Epub 2014 Sep 28.
352 Cooperative STAT/NF-B signaling regulates lymphoma metabolic reprogramming and aberrant GOT2 expression.Nat Commun. 2018 Apr 17;9(1):1514. doi: 10.1038/s41467-018-03803-x.
353 Acidosis decreases c-Myc oncogene expression in human lymphoma cells: a role for the proton-sensing G protein-coupled receptor TDAG8.Int J Mol Sci. 2013 Oct 11;14(10):20236-55. doi: 10.3390/ijms141020236.
354 Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints.Oncogene. 2009 Nov 12;28(45):3997-4008. doi: 10.1038/onc.2009.258. Epub 2009 Aug 31.
355 Epigenetic control via allosteric regulation of mammalian protein arginine methyltransferases.Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10101-10106. doi: 10.1073/pnas.1706978114. Epub 2017 Sep 5.
356 Heterogeneous epigenetic regulation of HACE1 in Burkitt- Lymphoma-derived cells.Leuk Res. 2017 Sep;60:53-57. doi: 10.1016/j.leukres.2017.06.006. Epub 2017 Jun 16.
357 The TP53-Induced Glycolysis and Apoptosis Regulator mediates cooperation between HTLV-1 p30(II) and the retroviral oncoproteins Tax and HBZ and is highly expressed in an in vivo xenograft model of HTLV-1-induced lymphoma.Virology. 2018 Jul;520:39-58. doi: 10.1016/j.virol.2018.05.007. Epub 2018 May 26.
358 Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.Immunology. 2017 Nov;152(3):472-483. doi: 10.1111/imm.12784. Epub 2017 Jul 27.
359 Polymorphism in the tumor necrosis factor-alpha promotor region and in the heat shock protein 70 genes associated with malignant tumors.Cancer. 1997 Oct 15;80(8):1489-96. doi: 10.1002/(sici)1097-0142(19971015)80:8<1489::aid-cncr17>3.0.co;2-1.
360 Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.Blood. 2017 Jan 26;129(4):473-483. doi: 10.1182/blood-2016-07-729954. Epub 2016 Nov 14.
361 IBTK contributes to B-cell lymphomagenesis in E-myc transgenic mice conferring resistance to apoptosis.Cell Death Dis. 2019 Apr 11;10(4):320. doi: 10.1038/s41419-019-1557-6.
362 Interleukin-25 Axis Is Involved in the Pathogenesis of Human Primary and Experimental Murine Sjgren's Syndrome.Arthritis Rheumatol. 2018 Aug;70(8):1265-1275. doi: 10.1002/art.40500. Epub 2018 Jun 27.
363 Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma.J Exp Clin Cancer Res. 2016 Jul 1;35(1):106. doi: 10.1186/s13046-016-0374-3.
364 Establishment and characterization of a novel VEGF-producing HHV-8-unrelated PEL-like lymphoma cell line, OGU1.Eur J Haematol. 2016 Feb;96(2):144-51. doi: 10.1111/ejh.12559. Epub 2015 Apr 21.
365 IRF4 promotes Epstein-Barr virus activation in Burkitt's lymphoma cells.J Gen Virol. 2019 May;100(5):851-862. doi: 10.1099/jgv.0.001249. Epub 2019 Mar 25.
366 Expression of interferon regulatory factor 7 correlates with the expression of Epstein-Barr Virus latent membrane protein 1 and cervical lymph node metastasis in nasopharyngeal cancer.Pathol Int. 2017 Sep;67(9):461-466. doi: 10.1111/pin.12561. Epub 2017 Jul 16.
367 An RNA Aptamer-Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients.Cancer Immunol Res. 2019 Sep;7(9):1511-1522. doi: 10.1158/2326-6066.CIR-18-0821. Epub 2019 Aug 5.
368 ISL-1 is overexpressed in non-Hodgkin lymphoma and promotes lymphoma cell proliferation by forming a p-STAT3/p-c-Jun/ISL-1 complex.Mol Cancer. 2014 Jul 29;13:181. doi: 10.1186/1476-4598-13-181.
369 The ITM2B (BRI2) gene is a target of BCL6 repression: Implications for lymphomas and neurodegenerative diseases.Biochim Biophys Acta. 2015 May;1852(5):742-8. doi: 10.1016/j.bbadis.2014.12.018. Epub 2014 Dec 31.
370 Pro-apoptotic and antiproliferative activity of human KCNRG, a putative tumor suppressor in 13q14 region.Tumour Biol. 2010 Jan;31(1):33-45. doi: 10.1007/s13277-009-0005-0. Epub 2009 Dec 18.
371 Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases.PLoS One. 2015 Feb 20;10(2):e0117420. doi: 10.1371/journal.pone.0117420. eCollection 2015.
372 Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cells. Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):14920-5. doi: 10.1073/pnas.0904231106. Epub 2009 Aug 12.
373 Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.Haematologica. 2018 Apr;103(4):679-687. doi: 10.3324/haematol.2017.182444. Epub 2018 Jan 5.
374 Safety study of culinary-medicinal Royal Sun Agaricus, Agaricus brasiliensis S. Wasser et al. KA21 (higher Basidiomycetes) assessed by prokaryotic as well as eukaryotic systems.Int J Med Mushrooms. 2012;14(2):135-48. doi: 10.1615/intjmedmushr.v14.i2.20.
375 A gene panel, including LRP12, is frequently hypermethylated in major types of B-cell lymphoma.PLoS One. 2014 Sep 16;9(9):e104249. doi: 10.1371/journal.pone.0104249. eCollection 2014.
376 MEF2B Instructs Germinal Center Development and Acts as an Oncogene in B Cell Lymphomagenesis.Cancer Cell. 2018 Sep 10;34(3):453-465.e9. doi: 10.1016/j.ccell.2018.08.006.
377 Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes.Nat Commun. 2018 Aug 24;9(1):3417. doi: 10.1038/s41467-018-05979-8.
378 Constitutional mismatch repair deficiency and childhood leukemia/lymphoma--report on a novel biallelic MSH6 mutation.Haematologica. 2010 May;95(5):841-4. doi: 10.3324/haematol.2009.015503. Epub 2009 Dec 16.
379 Mice deficient in MIM expression are predisposed to lymphomagenesis.Oncogene. 2012 Jul 26;31(30):3561-8. doi: 10.1038/onc.2011.509. Epub 2011 Nov 14.
380 An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo.J Immunol. 2012 Sep 1;189(5):2290-9. doi: 10.4049/jimmunol.1103495. Epub 2012 Jul 30.
381 The B7 Family Member B7-H6: a New Bane of Tumor.Pathol Oncol Res. 2018 Oct;24(4):717-721. doi: 10.1007/s12253-017-0357-5. Epub 2017 Oct 31.
382 Nfe2l3 (Nrf3) deficiency predisposes mice to T-cell lymphoblastic lymphoma.Blood. 2011 Feb 10;117(6):2005-8. doi: 10.1182/blood-2010-02-271460. Epub 2010 Dec 8.
383 Small cell lung cancer mimicking lymphoma in CT and 68Ga-DOTA-NOC PET/CT: A case report.Medicine (Baltimore). 2018 Jun;97(25):e11159. doi: 10.1097/MD.0000000000011159.
384 Cyclic Cystine-Bridged Peptides from the Marine Sponge Clathria basilana Induce Apoptosis in Tumor Cells and Depolarize the Bacterial Cytoplasmic Membrane.J Nat Prod. 2017 Nov 22;80(11):2941-2952. doi: 10.1021/acs.jnatprod.7b00477. Epub 2017 Nov 2.
385 Expression of splice variants of cancer-testis genes ODF3 and ODF4 in the testis of a prostate cancer patient.Genet Mol Res. 2012 Oct 4;11(4):3642-8. doi: 10.4238/2012.October.4.11.
386 Collagen prolyl hydroxylase 3 has a tumor suppressive activity in human lung cancer.Exp Cell Res. 2018 Feb 1;363(1):121-128. doi: 10.1016/j.yexcr.2017.12.020. Epub 2017 Dec 23.
387 The JAK inhibitor antcin H exhibits direct anticancer activity while enhancing chemotherapy against LMP1-expressed lymphoma.Leuk Lymphoma. 2019 May;60(5):1193-1203. doi: 10.1080/10428194.2018.1512709. Epub 2018 Oct 2.
388 A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.J Clin Pharmacol. 2018 Jan;58(1):114-121. doi: 10.1002/jcph.987. Epub 2017 Aug 7.
389 The prohibitin protein complex promotes mitochondrial stabilization and cell survival in hematologic malignancies.Oncotarget. 2017 Jul 1;8(39):65445-65456. doi: 10.18632/oncotarget.18920. eCollection 2017 Sep 12.
390 Reduced expression of the tumor suppressor PHLPP1 enhances the antiapoptotic B-cell receptor signal in chronic lymphocytic leukemia B-cells.Leukemia. 2010 Dec;24(12):2063-71. doi: 10.1038/leu.2010.201. Epub 2010 Sep 23.
391 Profiling the expression pattern of GPI transamidase complex subunits in human cancer.Mod Pathol. 2008 Aug;21(8):979-91. doi: 10.1038/modpathol.2008.76. Epub 2008 May 16.
392 Prep1 (pKnox1)-deficiency leads to spontaneous tumor development in mice and accelerates EmuMyc lymphomagenesis: a tumor suppressor role for Prep1.Mol Oncol. 2010 Apr;4(2):126-34. doi: 10.1016/j.molonc.2010.01.001. Epub 2010 Jan 7.
393 Silencing of CKIP-1 promotes tumor proliferation and cell adhesion-mediated drug resistance via regulating AKT activity in non-Hodgkin's lymphoma.Oncol Rep. 2017 Jan;37(1):622-630. doi: 10.3892/or.2016.5233. Epub 2016 Nov 8.
394 Female GADD34 mice develop age-related inflammation and hepatocellular carcinoma.Geriatr Gerontol Int. 2017 Dec;17(12):2593-2601. doi: 10.1111/ggi.13080. Epub 2017 Jun 21.
395 A Noncanonical Function of Polycomb Repressive Complexes Promotes Human Cytomegalovirus Lytic DNA Replication and Serves as a Novel Cellular Target for Antiviral Intervention.J Virol. 2019 Apr 17;93(9):e02143-18. doi: 10.1128/JVI.02143-18. Print 2019 May 1.
396 IFR4/MUM1-positive lymphoma in Waldeyer ring with co-expression of CD5 and CD10.Pediatr Blood Cancer. 2017 Feb;64(2):311-314. doi: 10.1002/pbc.26236. Epub 2016 Sep 12.
397 CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells.Oncogene. 2017 Feb 16;36(7):933-941. doi: 10.1038/onc.2016.259. Epub 2016 Aug 1.
398 A Rapid Embryonic Stem Cell-Based Mouse Model for B-cell Lymphomas Driven by Epstein-Barr Virus Protein LMP1.Cancer Immunol Res. 2015 Jun;3(6):641-9. doi: 10.1158/2326-6066.CIR-15-0058. Epub 2015 May 1.
399 An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup.Blood. 2015 Feb 5;125(6):959-66. doi: 10.1182/blood-2013-06-507152. Epub 2014 Nov 13.
400 Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol. 2008 May;30(5):347-52.
401 Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas.Blood. 2013 Apr 11;121(15):2964-74. doi: 10.1182/blood-2012-08-446096. Epub 2013 Feb 12.
402 The role of a newly identified SET domain-containing protein, SETD3, in oncogenesis.Haematologica. 2013 May;98(5):739-43. doi: 10.3324/haematol.2012.066977. Epub 2012 Oct 12.
403 Novel mutations in ataxia telangiectasia and AOA2 associated with prolonged survival.J Neurol Sci. 2013 Dec 15;335(1-2):134-8. doi: 10.1016/j.jns.2013.09.014. Epub 2013 Sep 17.
404 CREB targets define the gene expression signature of malignancies having reduced levels of the tumor suppressor tristetraprolin.PLoS One. 2014 Dec 26;9(12):e115517. doi: 10.1371/journal.pone.0115517. eCollection 2014.
405 Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis.Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3111-6. doi: 10.1073/pnas.0910667107. Epub 2010 Feb 1.
406 Smarcal1 and Zranb3 Protect Replication Forks from Myc-Induced DNA Replication Stress.Cancer Res. 2019 Apr 1;79(7):1612-1623. doi: 10.1158/0008-5472.CAN-18-2705. Epub 2019 Jan 4.
407 Epigenetic regulator Smchd1 functions as a tumor suppressor.Cancer Res. 2013 Mar 1;73(5):1591-9. doi: 10.1158/0008-5472.CAN-12-3019. Epub 2012 Dec 26.
408 Colorectal cancer DNA methylation marker panel validated with high performance in Non-Hodgkin lymphoma.Epigenetics. 2014 Mar;9(3):428-36. doi: 10.4161/epi.27554. Epub 2013 Dec 20.
409 SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway.Cancer Sci. 2016 Sep;107(9):1270-80. doi: 10.1111/cas.13001. Epub 2016 Sep 6.
410 STAT4, TRAF3IP2, IL10, and HCP5 Polymorphisms in Sjgren's Syndrome: Association with Disease Susceptibility and Clinical Aspects.J Immunol Res. 2019 Feb 10;2019:7682827. doi: 10.1155/2019/7682827. eCollection 2019.
411 Expression of SSX genes in human tumors.Int J Cancer. 1998 Jul 3;77(1):19-23. doi: 10.1002/(sici)1097-0215(19980703)77:1<19::aid-ijc4>3.0.co;2-2.
412 Signal transducer and activator of transcription (STAT)-5: an opportunity for drug development in oncohematology.Oncogene. 2019 Jun;38(24):4657-4668. doi: 10.1038/s41388-019-0752-3. Epub 2019 Feb 19.
413 Development of classical Hodgkin's lymphoma in an adult with biallelic STXBP2 mutations.Haematologica. 2013 May;98(5):760-4. doi: 10.3324/haematol.2012.073098. Epub 2012 Oct 25.
414 Silencing P2X7 receptor downregulates the expression of TCP-1 involved in lymphoma lymphatic metastasis.Oncotarget. 2015 Dec 8;6(39):42105-17. doi: 10.18632/oncotarget.5870.
415 Association between lymphoma prognosis and aberrant methylation of ID4 and ZO-1 in bone marrow and paraffin-embedded lymphoma tissues of treatment-naive patients.Oncol Rep. 2013 Jul;30(1):455-61. doi: 10.3892/or.2013.2450. Epub 2013 May 10.
416 Pro-death and pro-survival properties of ouabain in U937 lymphoma derived cells.J Exp Clin Cancer Res. 2012 Nov 15;31(1):95. doi: 10.1186/1756-9966-31-95.
417 Abnormal accumulation of human transmembrane (TMEM)-176A and 176B proteins is associated with cancer pathology.Acta Histochem. 2012 Nov;114(7):705-12. doi: 10.1016/j.acthis.2011.12.006. Epub 2012 Jan 12.
418 Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types.Int J Cancer. 2004 May 1;109(5):786-92. doi: 10.1002/ijc.20041.
419 Need for an improved molecular/genetic classification for CD30+ lymphomas involving the skin.Cancer Control. 2007 Apr;14(2):124-32. doi: 10.1177/107327480701400205.
420 The Upregulation of TRAF1 Induced by Helicobacter pylori Plays an Antiapoptotic Effect on the Infected Cells.Helicobacter. 2016 Dec;21(6):554-564. doi: 10.1111/hel.12311. Epub 2016 Apr 6.
421 Signaling mechanisms of bortezomib in TRAF3-deficient mouse B lymphoma and human multiple myeloma cells.Leuk Res. 2016 Feb;41:85-95. doi: 10.1016/j.leukres.2015.12.005. Epub 2015 Dec 19.
422 TREX1 variants in Sjogren's syndrome related lymphomagenesis.Cytokine. 2020 Aug;132:154781. doi: 10.1016/j.cyto.2019.154781. Epub 2019 Jul 18.
423 TRIM65 is a potential oncogenic protein via ERK1/2 on Jurkat and Raji cells: A therapeutic target in human lymphoma malignancies.Cell Biol Int. 2018 Nov;42(11):1503-1510. doi: 10.1002/cbin.11035. Epub 2018 Sep 11.
424 TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma.Blood. 2018 Jun 21;131(25):2789-2802. doi: 10.1182/blood-2017-09-806679. Epub 2018 Apr 13.
425 T-cell regulation by casitas B-lineage lymphoma (Cblb) is a critical failsafe against autoimmune disease due to autoimmune regulator (Aire) deficiency.Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14709-14. doi: 10.1073/pnas.1009209107. Epub 2010 Jul 28.
426 The SRC family kinase LYN redirects B cell receptor signaling in human SLP65-deficient B cell lymphoma cells.Oncogene. 2006 Aug 17;25(36):5056-62. doi: 10.1038/sj.onc.1209510. Epub 2006 Mar 27.
427 A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation.Blood. 2009 May 21;113(21):5206-16. doi: 10.1182/blood-2008-09-179762. Epub 2009 Mar 25.
428 FcRL4(+) B-cells in salivary glands of primary Sjgren's syndrome patients.J Autoimmun. 2017 Jul;81:90-98. doi: 10.1016/j.jaut.2017.03.012. Epub 2017 Apr 6.
429 Gene expression profiling in lymphoma diagnosis and management.Best Pract Res Clin Haematol. 2009 Jun;22(2):191-210. doi: 10.1016/j.beha.2009.05.001.
430 Granulysin-mediated tumor rejection in transgenic mice.J Immunol. 2007 Jan 1;178(1):77-84. doi: 10.4049/jimmunol.178.1.77.
431 Overexpression of a transcription factor LYL1 induces T- and B-cell lymphoma in mice.Oncogene. 2007 Oct 18;26(48):6937-47. doi: 10.1038/sj.onc.1210494. Epub 2007 May 7.
432 Differential expression of the human MIXL1 gene product in non-Hodgkin and Hodgkin lymphomas.Hum Pathol. 2007 Mar;38(3):500-7. doi: 10.1016/j.humpath.2006.09.020.
433 Anaplastic plasmacytoma of mouse--establishing parallels between subtypes of mouse and human plasma cell neoplasia.J Pathol. 2010 Jul;221(3):242-7. doi: 10.1002/path.2714.
434 Defects of FA/BRCA pathway in lymphoma cell lines.Int J Hematol. 2008 Dec;88(5):543-550. doi: 10.1007/s12185-008-0199-8. Epub 2008 Nov 15.
435 The CALM and CALM/AF10 interactor CATS is a marker for proliferation.Mol Oncol. 2008 Dec;2(4):356-67. doi: 10.1016/j.molonc.2008.08.001. Epub 2008 Sep 4.
436 Gene amplification and associated loss of 5' regulatory sequences of CoAA in human cancers.Oncogene. 2007 Feb 8;26(6):822-35. doi: 10.1038/sj.onc.1209847. Epub 2006 Jul 31.
437 RGS1 and RGS13 mRNA silencing in a human B lymphoma line enhances responsiveness to chemoattractants and impairs desensitization.J Leukoc Biol. 2006 Jun;79(6):1357-68. doi: 10.1189/jlb.1105693. Epub 2006 Mar 24.
438 Ribosomal Protein Rpl22 Controls the Dissemination of T-cell Lymphoma.Cancer Res. 2016 Jun 1;76(11):3387-96. doi: 10.1158/0008-5472.CAN-15-2698. Epub 2016 Apr 5.
439 Molecular profiling of CD3-CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways.Blood. 2009 Oct 1;114(14):2969-83. doi: 10.1182/blood-2008-08-175091. Epub 2009 Jul 16.
440 Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas.Blood. 2008 Jan 1;111(1):351-8. doi: 10.1182/blood-2007-06-094151. Epub 2007 Sep 26.